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Abstract
Chronic obstructive pulmonary disease (COPD), a progressive and nonreversible disease,
is a leading cause of mortality and morbidity throughout the world. Detecting COPD
early in the disease process will help in decreasing later stage COPD severity. Because
airway inflammation is a hallmark of COPD, it has been proposed that measuring exhaled
nitric oxide, a marker of inflammation, in exhaled breath condensate could prove to be an
inexpensive and efficient method to detect COPD in outpatient settings. Using the
hypothetico-deductive theory as a guideline, this study used secondary data from the
National Health and Nutrition Examination Survey 2007 to 2010 to test the association
between exhaled nitric oxide (eNO), COPD, and COPD severity. In addition, this study
explored whether occupation modifies the association between eNO and COPD.
Descriptive statistics, chi-square analyses, and regression analyses were used to analyze
data from a sample size of 10,214 individuals. The prevalence of COPD was 7.2%, based
on self-reported physician diagnoses and 11.4% based on prebronchodilator spirometry
analysis, strengthening the argument that COPD is often under- or misdiagnosed in
clinical settings. This study found no statistically significant association between eNO,
COPD, and COPD severity, and occupational status did not appear to modify the
association between eNO and COPD. The findings of this study highlight the importance
of using objective measures such as spirometry in clinical settings for early diagnosis and
management of COPD. Early diagnosis helps to slow the progression of the disease,
resulting in fewer related comorbidities and complications.
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Chapter 1: Introduction to the Study
Background of the Study
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality
and morbidity throughout the world. While many medical causes of death are
decreasing, COPD is on the rise. In 2005, 5% of all deaths worldwide were due to COPD
complications (World Health Organization, 2011). This percentage is predicted to
increase by 30% by 2020, and COPD is on target to become the third leading cause of
death worldwide (World Health Organization, 2011).
COPD comprises two subgroups of disease: chronic bronchitis and emphysema.
Since there is no cure for COPD, the focus is on early diagnosis, treatment, and
prevention. The two main methods for diagnosing COPD are spirometry and sputum
induction tests. Spirometry determines lung function as a ratio of expired air and lung
function, and the sputum test analyzes bacteria and fungi to help establish the stage of the
disease. Although both are considered noninvasive, neither is suited for outpatient
testing. Sputum induction is too time-consuming—it takes 30 to 45 minutes to complete,
requires a lab analysis, and depends upon the patient’s ability to produce a sputum
sample at the time of testing. Spirometry testing requires a trained medical professional
to administer and read the results. One promising technique for use in outpatient settings
measures is exhaled breath condensate (EBC) using GC-MS, eNose, or similar methods.
The advantage of these methods is that mediators found in exhaled breath, such as
exhaled nitric oxide (eNO), may correlate with airway inflammation and disease
progression in COPD. If eNO is associated with COPD, then methods could be
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developed to test eNO in outpatient settings, providing public health professionals an
important and inexpensive tool to diagnose the type and possibly level of COPD severity.
Airway inflammation is a hallmark of COPD and asthma. Nitric oxide (NO) is
naturally produced in the body and helps fight inflammation. Elevated NO levels
observed in the EBC of asthmatic patients are used to diagnose and manage asthma in
clinical settings (Djukanovic & Gadola, 2008). However, the role eNO plays in COPD is
inconclusive, with some studies finding a positive correlation (Brindicci et al., 2005),
others reporting a negative association (Beg, Alzoghaibi, Abba, & Habib, 2009), and
some finding none (Bazeghi, Gerds, Budtz-Jørgensen, Hove, & Vestbo, 2011). This
study took a different approach from current research and analyzed combined data from
NHANES 2007–2008 and 2009–2010 to determine associations between eNO, COPD
(chronic bronchitis or emphysema), and COPD severity. Patients’ occupations are
seldom reported in the current literature examining the association between eNO and
COPD (Bazeghi et al., 2011; Bhowmik, Seemungal, Donaldson, & Wedzicha, 2005;
Brindicci et al., 2005; Lehouck, Carremans, De Bent, Decramer, & Janssens, 2010; Liu,
Sandrini, Thurston, Yates, & Thomas, 2007). Therefore, in this study, I also examined
whether occupation modifies the association between eNO and COPD. More information
is provided in Chapter 2.
Problem Statement
COPD is often under- or misdiagnosed in the primary care setting (Jochmann et
al., 2010; Lehouck et al., 2010; Smidth, Sokolowski, Kærsvang, & Vedsted, 2012;
Spyratos, Chloros, & Sichletidis, 2012). Spirometry, the current gold standard for
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diagnosing COPD, is often underutilized or used incorrectly (Spyratos et al., 2012).
Therefore, a noninvasive method to diagnose COPD in primary care settings is needed.
NO analysis from EBC is a promising technique which is quick, easy to use, and highly
reproducible (Beg et al., 2009).
NO and NO derivatives are known markers of airway inflammation present in
EBC of asthma patients. However, studies on the correlation between NO derivatives,
airway inflammation, and COPD severity are inconclusive; some have shown an
association between eNO and COPD (Beg et al., 2009; Brindicci et al., 2005), whereas
others have not (Bazeghi et al., 2011). If eNO levels correlate with inflammation and
COPD severity, their measurement would allow public health and clinical professionals
to use eNO levels to quickly diagnose COPD severity in outpatient settings. This method
is noninvasive and requires less time and expertise than either sputum induction tests or
spirometry. Public health professionals agree that a noninvasive method based on EBC is
needed for outpatient settings (Fens et al., 2009; Holz et al., 2008). Associating eNO
with airway inflammation in COPD would be a step in that direction.
Purpose of the Study
The purpose of this quantitative study was to determine if there is an association
between eNO, COPD subgroups, and COPD severity, using the NHANES 2007 to 2010
data. In addition, I explored effect modification by occupational status. COPD and
COPD severity, as defined by the Global Initiative for Lung Disease (GOLD) standard,
were dependent variables. Exhaled NO was the independent variable. Exhaled NO is a
marker for inflammation in exhaled breath condensate for asthma, but has not been
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proven conclusively to be a marker for airway inflammation in COPD studies. As
previously stated, Beg et al. (2009) and Brindicci et al. (2005) have shown a correlation,
and Bazeghi et al. (2011) showed none. (Detailed information on these and other studies
is presented in Chapter 2.) One major limitation of past studies was low sample size: the
average sample size was 80 (range: 20 to 176) with an average of 53 COPD participants
in each study (range: 14 to 91). A second limitation is that no researchers have yet
examined the possible modifying role of occupational status upon both eNO and COPD.
NHANES collected information on self-reported chronic bronchitis and emphysema and
measured FEV1, FVC, and eNO from a large representative sample during its 2007 to
2010 data collection cycles. The presence of these data along with self-reported
occupational history provided the opportunity to study the association between eNO,
COPD, and COPD severity in a single study. The measurement of eNO in EBC is
noninvasive and quick and easy to perform. If it is positively correlated with COPD, it
has the potential to replace sputum tests for diagnosis and management.
Theoretical Framework
This dissertation was guided by the hypothetico-deductive theory, which is based
on formulating and testing a hypothesis or hypotheses by deduction analysis (Ludan,
1982). These deductions are tested in controlled experiments. Hypotheses that are
falsified are rejected and replaced by new hypotheses. The hypothetico-deductive theory
has been around for hundreds of years and tested and debated by such historical figures
as Rene Decartes, David Hume, and Issac Newtown (Ludan, 1982). Detailed information
on the theoretical framework is presented in Chapter 2.
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Research Questions and Hypotheses
I examined the associations between eNO, COPD, and COPD severity and the
effect of the role of occupation on these associations. The research questions and the
hypotheses for the study were as follows:


Research Question 1: Is there an association between eNO and COPD (chronic
bronchitis or emphysema) in adults?
o Hypothesis 1: There is an association between eNO and self-reported,
physician-diagnosed COPD (defined as presence of chronic bronchitis or
emphysema) among adult NHANES 2007 to 2010 participants.
o Hypothesis 2: Increasing eNO levels are associated with increased COPD
severity, as defined by the GOLD standard.



Research Question 2: Does occupation modify the association between eNO and
COPD?
o Hypothesis 3: The association between NO and COPD is modified by
occupation.
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Definition of Terms


Chronic Obstructive Pulmonary Disease (COPD): COPD is a slowly progressive,
preventable, treatable heterogeneous, multiphenotypic disease that is
characterized by limitations of airflow due to inflammation that are not fully
reversible and not curable (Basanta et al., 2010; Ferrara, 2011; Garvey, 2011;
WHO, 2011). Alternative names for COPD include chronic obstructive airway
disease, chronic obstructive lung disease, chronic bronchitis, emphysema, and
bronchitis chronic (MedlinePlus, 2011). However, chronic bronchitis and
emphysema are the major forms of COPD.



Exhaled breath condensate (EBC) collection: EBC collection is a noninvasive
means to collect breath samples from the lungs. There are many types of
mediators within the lungs that are causes of disease and can be regulated by
therapeutics (Horváth et al., 2005).



Global Initiative for Chronic Obstructive Lung Disease (GOLD): The GOLD
standard defines four stages of COPD ranging from mild (Stage I) to severe
(Stage IV). Each stage is characterized by the airflow limitations calculated by
spirometry. A patient classified as Stage I may not be able to sense an abnormal
airflow, whereas a person with Stage IV may have chronic respiratory failure and
terminal exacerbations. More information is given in Table 4.



Nitric Oxide (NO): There are several derivatives of NO. Fractional exhaled nitric
oxide (FENO) in exhaled breath allows public health professionals to assess
airway inflammation. Other derivatives include alveolar nitric oxide concentration
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(CalvNO) and bronchial nitric oxide concentration (JawNO) (Lehouck et al.
2010). I use exhaled nitric oxide (eNO) to represent exhaled nitric oxide,
including FENO.


Spirometry: This method compares the amount of air a person can forcibly exhale
in the first second of one breath (FEV1) with the amount of total air exhaled in
one breath (FVC). The normal FEV1/FVC ratio is 70 to 80% (GOLD, 2010).



Sputum induction: This is a noninvasive method in which sputum (a combination
of mucus and saliva) is expelled from the lungs with the help of a nebulizer. The
sputum is then collected and analyzed for disease biomarkers (Grant, Hammitt,
Murdoch, O'Brien, & Scott, 2012).
Assumptions and Limitations
The NHANES public use data were used in the study, and it was assumed that the

sample is representative of noninstitutionalized adults in the United States. It was further
assumed that the data—self-reports, FEV1, FVC, and eNO—were collected according to
the established guidelines without any measurement error. Lastly, it was assumed that
eNO levels reflect true underlying airway inflammation.
One of the limitations of this study is that self-reported data from the interviews
may be subject to recall bias. This bias may be introduced into the study if the patients do
not accurately recall reporting information related to certain confounding variables
affecting NO levels, such as eating nitrogen-rich foods, smoking, and taking medications.
In addition, misclassification bias due to measurement error in administering the
spirometry and measuring eNO is also possible. However, it is believed that this bias was
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minimized by the rigorous collection and recording procedures adopted by the NHANES
survey. Lastly, self-reported occupation data did not have sufficient detail to determine
the potential or actual amount of occupational exposure to harmful particles, gases, and
fumes to quantify eNO.
Significance of the Study
The study has several positive public health implications. The first is that COPD
is often misdiagnosed or underdiagnosed in primary care settings (Jochmann et al., 2010;
Lehouck et al., 2010; Smidth et al., 2012; Spyratos et al., 2012). Early diagnosis can
slow or stop the disease progression by convincing the patient to alter habits, behaviors,
or lifestyle, such as quitting smoking (Jochmann et al., 2010; Minas et al., 2010).
Currently there is no noninvasive technique that is quick and easy to use in outpatient
settings. The availability of noninvasive diagnostic methods could help field medical
professionals such as those in mobile health units to reach out to the underserved
population, especially in developing countries, to provide and monitor medical care.
Early diagnosis of COPD could help decrease the incidence and prevalence of later stage
COPD and ultimately could decrease comorbidities and mortality rates caused by COPD.
Measuring eNO in EBC is a promising noninvasive method that would allow
physicians and public health professionals to monitor the progression of COPD in
outpatient settings with minimal training.
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Implications for Social Change
The implications for positive social change were that individuals can be
diagnosed with a noninvasive method more quickly and safely than with traditional
methods. Used in preventative screenings, such a method could result in early diagnosis
and treatment to prevent the severe later stage forms of COPD. Patients’ quality of life
will increase, associated comorbidities will decrease, and mortality rates will decline.
Summary and Transition
Sputum induction is the current gold standard for determining phenotypes of
COPD. However, sputum induction is too time-consuming and labor intensive for use in
outpatient settings. Researchers agree that a new noninvasive method is needed for the
clinical setting (Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012;
Spyratos et al., 2012). Although gas chromatography–mass spectrometry (GC-MS),
electronic noses (eNoses), and similar devices can differentiate between different
respiratory diseases such as asthma and COPD, there is no current EBC diagnostic
technology that can uncover COPD heterogeneity. In addition, studies correlating eNO
to inflammation and COPD severity have been inconclusive as seen in conflicting results
from several studies (Bazeghi et al., 2011; Brindicci et al., 2005).
Therefore, in this study, I attempted to improve upon past research by analyzing
eNO levels and comparing them with diagnoses of chronic bronchitis and emphysema
and documented levels of severity in a larger sample size obtained through NHANES
data from 2007 to 2010. In addition, through the second research question, I investigated
whether the association between eNO and COPD is modified by occupation. If eNO
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levels are correlated with airway inflammation in different forms of COPD subgroups
and severity, the measurement of eNO could be used to develop methods for EBC testing.
This could lead to more patients tested in outpatient settings as a preventive measure and
eventually could lead to early treatment that would result in a decrease in later-stage
COPD cases and COPD-related comorbidities, lower healthcare costs, and eventually a
decrease in COPD-related mortality.
In Chapter 2, I review the literature related to eNO and COPD and outline the
theoretical framework of this study. The GOLD standard, spirometry, and the role of
occupation are also discussed. Chapter 3 outlines the research methodology; describes
the dependent, independent, and confounding variables; and explains the statistical
analysis. The results of this study are reported in Chapter 4, and the summary, discussion,
and conclusions are presented in Chapter 5.
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Chapter 2: Literature Review
Background
Current methods for diagnosing COPD in the primary care setting, such as
spirometry are underutilized, attributing to the misdiagnoses of COPD in primary care
(Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012; Spyratos et al., 2012).
Therefore, a noninvasive method that is quick and easy to use is needed. A promising
technique is analyzing eNO from EBC. The rationale is that airway inflammation is
found in all forms of COPD. NO and NO derivatives are known markers of airway
inflammation present in EBC. Research has shown a correlation between eNO and
inflammation in asthma patients. However, there is no conclusive association between
NO derivatives, airway inflammation, and COPD severity. Therefore, the purpose of this
study was twofold. The first objective was to investigate the association between eNO
and COPD and eNO and COPD severity using NHANES data from 2007 to 2010. The
second was to investigate whether the association between eNO and COPD is modified
by occupation. This study used a larger sample size than previous studies and compared
eNO, COPD (emphysema, chronic bronchitis), and COPD severity, where most recent
research has focused on eNO and COPD or eNO and COPD severity, not both (Beg et al.,
2009; Brindicci et al., 2005; Liu et al., 2007). In addition, I investigated whether the
association between eNO and COPD is modified by occupation.
I begin this chapter with reviewing basic information on COPD including
prevalence and incidence, causes, at-risk population, diagnosis, mortality, and costs.
More detailed information follows, with sections on epidemiology; risk factors ranging
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from tobacco use to genetics; symptoms; and exacerbations. I continue with detailed
sections on methods for diagnosis such as sputum induction, spirometry, and EBC. I
conclude with general information on NO leading into a more detailed discussion on the
association between eNO and COPD (chronic bronchitis, emphysema), eNO and COPD
severity, and NO from occupational exposure. Table 1 gives the key databases used, and
Table 2 lists key search terms.
Literature Search Strategy
Table 1
Key Databases Used
Key Databases Used
Walden University Library – Thoreau
Walden University Library – Medline with Full Text
Walden University CINAHL Plus with Full Text
Google: Google Scholar
Google: Google Search Engine
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Table 2
Key Search Terms
Search terms
























Chronic Bronchitis
Chronic Obstructive Pulmonary
Disease
Chronic Obstructive Pulmonary
Disease, by country
Chronic Obstructive Pulmonary
Disease, Costs
Chronic Obstructive Pulmonary
Disease, EBC
Chronic Obstructive Pulmonary
Disease, Epidemiology EBC
Chronic Obstructive Pulmonary
Disease, Specific Author Name
Exhaled Breath Condensate
COPD
COPD, Costs
COPD, EBC
COPD, Europe
COPD, Exhaled Breath Condensate
COPD, NHANES
COPD, NO, NHANES
Diagnosis, COPD
Diagnosis, Chronic Obstructive
Pulmonary Disease
Emphysema
Epidemiology COPD, Specific
Author Name
GOLD, Chronic Obstructive
Pulmonary Disease
GOLD, COPD
NHANES, Nitric, COPD,
Occupation
NHANES, Nitric, COPD, Job
NHANES, Nitric, COPD, Work




Nitric, COPD, NHANES
Nitric, Job



Nitric, Occupation



Nitric, Work



Nitric Oxide



Nitric Oxide, Inflammation



Nitric Oxide, Job











Nitric Oxide, NHANES
Nitric Oxide, Occupation
Nitric Oxide, Work
Nitric Oxide, Specific Author Name
NO, COPD, Job
NO, COPD, Occupation
NO, COPD, Work
NO, Inflammation
NO, NHANES




NO, Nitric
NO, Specific Author Name



Specific Author Name




Specific Title of a Paper
Spirometry



Sputum Induction
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Scope of Literature
The literature collected was published from 1995 to 2014. Research from 1995 to
2005 was used to provide a historical background and to frame the problem. Most data
came from recent literature dating from 2005 to 2014. Assessing the link between eNO
and COPD is a relatively new topic, and current literature was limited in the number and
size of the studies. Literature included in this study is from peer-reviewed sources,
scholarly articles, periodicals, journals, textbooks, websites, interviews, conferences, and
Internet sources. Table 3 gives examples of literature collected and analyzed for this
paper.
Table 3
Literature Included
Sources

Examples

Conferences

Breath Summit 2011

Internet sources

Center for Disease Control, World Health
Organization

Interviews

Dr. Susan Hausserman

Journals, peer-reviewed sources,

American Journal of Respiratory Care

Periodicals

Medicine

Scholarly articles

Journal of Breath Research

Textbooks

Health promotion planning and evaluation:
A practical, systemic approach for
community health
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Theoretical Framework
The hypothetico-deductive theory is based on formulating and testing a
hypothesis or hypotheses by deduction analysis. Deductions are tested by observations
and experiments. Hypotheses that are proven false are rejected and replaced by new
hypotheses (Oreskes, 2003). Figures 1, 2, and 3 are visual representations of the three
hypotheses in this study.

eNO – Quartile 1
Chronic
Bronchitis
eNO – Quartile 2
Exhaled Nitric
Oxide from EBC

COPD

eNO – Quartile 3
Emphysema

eNO – Quartile 4

Figure 1. Hypothesis 1: There is an association between eNO and COPD (chronic
bronchitis and emphysema).
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COPD Severity (Stage I)

Exhaled nitric Oxide
in Quartiles from
Figure 1

COPD Severity (Stage II)

COPD Severity (Stage III)
COPD Severity (Stage III)
COPD Severity (Stage IV)

Figure 2. Hypothesis 2: Increasing eNO levels are associated with increased COPD
severity, as defined by the GOLD standard.

No
Not At- Risk
Occupational Exposure
to Nitric Oxide

At-Risk
Yes

Figure 3. Hypothesis 3 – The association of eNO and COPD is modified by occupational
exposure.
Exhaled NO is a determinant of airway inflammation in asthma, and airway
inflammation is prevalent in all stages of COPD. Therefore, eNO may be a determinant
of airway inflammation for COPD, and eNO could be used as a noninvasive biomarker to
diagnose COPD. This is important, because this is a noninvasive, easy-to-use method
that could replace more invasive tests.
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The independent variable was eNO. The first hypothesis stated that eNO was
associated with COPD. The second hypothesis stated that there is an association between
eNO and COPD severity as categorized by the GOLD standard. Exhaled NO is a known
marker for airway inflammation in asthma, but its role in COPD is inconclusive. Through
the second research question, I investigated whether occupation modified the association
between eNO and COPD.
Introduction
COPD is a global disease contributing to an increase in morbidity and mortality
while causing higher medical costs and social economic burdens (Budweiser et al., 2007;
Rocker, Young, & Simpson, 2009; Tonello & Poli, 2011). In 2002, COPD was the fifth
leading cause of death (Tonello & Poli, 2011; World Health Organization, 2011). In
2004, COPD affected approximately 64 million people (World Health Organization,
2011). In 2005, 5% of deaths worldwide (3 million people) resulted from COPD (World
Health Organization, 2011). Ninety percent of COPD-related deaths were in low-income
to middle-income countries (World Health Organization, 2011). Total deaths are
expected to rise by 30% over the next decade if there are no interventions. Furthermore,
COPD is expected to become the third leading cause of death globally by 2020 (Bessa et
al., 2011; Rocker et al., 2009; World Health Organization, 2011). This projected increase
in mortality is due to the aging of the world’s population and the continued use of
tobacco (Malipatil & McDonald, 2009). In Western societies, many medical causes of
death are on the decline; however, the prevalence of morbidity and mortality of COPD in
both men and women is increasing (Rocker et al., 2009).
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COPD is a noncurable, slowly progressive, preventable but treatable
heterogeneous, multiphenotypic disease that is characterized by limitations of airflow due
to inflammation (Basanta et al., 2010; Garvey, 2011; World Health Organization, 2011).
Alternative names for COPD include chronic obstructive airway disease, chronic
obstructive lung disease, chronic bronchitis, emphysema, and bronchitis chronic
(MedlinePlus, 2011). However, chronic bronchitis and emphysema are the two dominant
forms of COPD, and most people have a combination of the two.
COPD is not fully reversible, and therefore the focus is not on curing the disease,
but on diagnosis, prevention, and treatment. Two major risk factors for COPD include
tobacco smoke and air pollutants (Hoth, Wamboldt, Bowler, Make, & Holm, 2011). For
example, in the United States, smoking played a role among 80% to 90% of COPD
patients (Hoth et al., 2011). Although COPD is prevalent in smokers, research has shown
that nonsmokers can also develop it because of genetic disposition (Nazir & Erbland,
2009). Studies have determined that mutations of a specific gene may cause COPD in
nonsmokers (Nazir & Erbland, 2009). COPD affects the entire body, including the heart,
kidneys, and muscles, and is associated with a large range of comorbidities, such as
cardiovascular disease, osteoporosis, and diabetes (Lynes, 2010). In addition, there are
emotional consequences of having COPD, as the patient’s quality of life (QoL) is
adversely affected. For example, individuals with COPD may experience difficulties in a
wide range of areas in their life, resulting in early retirement, financial stress, family
complications, changes in self-esteem, and lack of independence (Avsar & Kasikci,
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2010). In addition, recent studies have demonstrated that oxidative stress is a key risk
factor in the pathogenesis of COPD (Lee & Thomas, 2009).
COPD is a major contributor to death, disability, and financial burdens throughout
the world. As the population ages, COPD will continue to contribute to economic
hardships for several years (Hutchinson, Brand, Irving, Roberts, & Campbell, 2010). As
the prevalence and incidence rates of GOLD Stages III and IV increase, compared to
Stages I and II, the costs of COPD management will also increase. The advanced stages
of the disease consume a large proportion of health care resources due to excessive
hospitalizations, exacerbations, and mortality rates (Budweiser, Jorres, & Pfeifer, 2008).
Early diagnosis and treatment are key to controlling and decreasing COPD
incidence and prevalence rates. Currently, lung performance is assessed by spirometry,
which is accepted as a universal method, by public health professionals worldwide, to test
for COPD. This method measures the ratio of FEV1 to FVC. A healthy person has an
observed ratio of greater than or equal to 70% lung capacity. Individuals with a ratio of
less than 70% are considered to have some form of COPD (GOLD, 2010). The GOLD
standard lists four stages of COPD, with Stage I defined as mild COPD, and Stage IV as
very severe (see Table 4). Due to the slow progressive nature of the disease, COPD is
more frequently diagnosed in individuals over 40 years of age (World Health
Organization, 2011). However, many forms of treatment are available to aid in managing
symptoms and increasing QoL. Pharmacotherapy targeted at COPD includes the use of
bronchodilators, corticosteroids, antibacterial products, and/ or a mix of these
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pharmaceuticals (Nazir & Erbland, 2009). Table 4 gives the criteria for COPD severity
when tested by spirometry.
Table 4
GOLD Spirometry Criteria for COPD Severity
Severity

Characterized by airflow
limitation
FEV1/FVC < 0.70, FEV1
>= 80 % predicted

Criteria

Moderate (II)

FEV1/FVC < 0.70, 50 %
<= FEV1 <= 80 %
predicted

Symptoms usually progress
at this stage, with shortness
of breath typically developing
on exertion.

Severe (III)

FEV1/FVC < 0.70, 30 %
<= FEV1 <= 50 %
predicted

Shortness of breath typically
worsens at this stage and
often limits patients’ daily
activities. Exacerbations are
especially seen beginning at
this stage.

Very Severe (IV)

FEV1/FVC < 0.70, <30
% predicted or FEV1
<50 % predicted plus
chronic respiratory
failure

At this stage, quality of life
is very appreciably impaired
and exacerbations may be
life-threatening.

Mild (I)

At this stage, the patient
may not be aware that their
lung function is abnormal.

Note. Global Initiative for Chronic Obstructive Lung Disease. (2010). Spirometry for health care providers: Global Initiative for
Chronic Obstructive Lung Disease (GOLD). from http://www.goldcopd.org/uploads/users/files/GOLD_Spirometry_2010.pdf

COPD is underdiagnosed around the world (Jochmann et al., 2010; An Lehouck
et al., 2010). For example, in the United States, for every one person diagnosed with
COPD, there are another 1.4 people who have not been diagnosed and therefore not
captured in healthcare statistics (Garvey, 2011). Concerning healthcare utilization in the
United States, in 2000 there are approximately 8 million primary care provider and
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outpatient visits, 1.5 million emergency room visits and 726,000 hospitalizations due to
COPD (Garvey, 2011). In addition, 1 in 5 elderly in the United States are hospitalized
because of COPD (Avsar & Kasikci, 2010; Malipatil & McDonald, 2009). Estimated
annual COPD rates in other countries are 2.7 million in Germany, 300,000 in Australia,
200,000 in New Zealand, and 1.5 million in Spain (Avsar & Kasikci, 2010).
In 2005, COPD caused 126,005 deaths in the United States in persons 25 years
and older. This represented an 8% increase from 116,494 in 2000 (Caress, Luker, &
Chalmers, 2010). The United Kingdom estimates that there are between 25,000 and
30,000 COPD-related deaths per year (British Lung Foundation, 2011; Health and Safety
Executive, 2013). Approximately 15% of those admitted with COPD die within the
following 3 months, and 25% within 1 year of admission (British Lung Foundation,
2011; Trueman & Trueman, 2011).
Healthcare costs related to COPD have a significant impact throughout the world.
In 2001, 520 patients were admitted to UK hospitals. This equates to 4,156 beds or £1.13
million In Spain, 43.8% of all hospitalization costs and 40.3% of drug acquisition costs
are related to COPD (Banning, 2006). The cost of treating patients with exacerbated
COPD by the Canadian Healthcare system was approximately $750 million per year
(Rocker et al., 2009). A study on the economic burden in the United States concluded
that the cost per patient was between $2,700 and $5,900 per patient annually. In-patient
hospitalization accounted for close to 70% of all direct costs. One study estimates the
total costs due to COPD in the United States at $10 billion per year (Rocker et al., 2009).
Another estimates direct costs of COPD at $29.5 billion and indirect costs at $20.4 billion
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(GOLD, 2010). The healthcare cost for people with COPD are more than double of those
of age-matched peers (Rocker et al., 2009). In Europe, 6% of total healthcare costs are
related to respiratory diseases (Spyratos et al., 2012). COPD accounts for 50% of those
costs—38.6 billion euros per year(Spyratos et al., 2012).
The COPD drug market is estimated to increase from approximately $8.4 billion
in 2009 to more than $13 billion in 2019 in the US, France, Germany, Italy, Spain, UK,
and Japan (Business Wire, 2011). Forecasters believe that an expanding aging population
and improvements in diagnosis and drug treatment will drive market growth (Business
Wire, 2011). In addition, in the major pharmaceutical markets, the population that will
rely on drug treatments will increase 75%, from 18 million patients in 2009 to
approximately 24 million in 2019 (Business Wire, 2011).
High healthcare costs are evident before COPD diagnosis. One study, a
retrospective analysis of healthcare costs using matched cases and controls, determined
that costs were $1,182 higher 24 months prior to diagnosis of COPD and $2,489 higher
12 months before (Mapel et al., 2008). United States’ data for 2001, showed 110,000
deaths, 500,000 hospitalizations, and over $18 billion in direct medical expenditures
annually as a result of acute exacerbations of COPD (Hutchinson et al., 2010). The
implication is that these cost could be prevented or reduced with early diagnosis of
COPD.
Epidemiology/ Clinical - Demographics
COPD is a slow, progressive disease that typically affects people 40 years old and
older (World Health Organization, 2011). Men and women are equally affected by
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COPD. The World Health Organization attributes this to an increase in the incidence and
prevalence in women smokers in high-income countries (World Health Organization,
2011). A study using NHANES data from 1997 to 2004 showed a high incidence in
young women (5.4% 95% CI: 5.3-5.6) compared to men (2.8% 95% CI: 2.7-2.9)
validating the hypothesis that COPD is increasing among women (Bang, Syamial, &
Mazurek, 2009).
Emphysema and chronic bronchitis are the two dominant forms of COPD.
Emphysema is the destruction of the lung over time by enlargement of and destruction of
air sacs (Ferrara, 2011; MedlinePlus, 2011). Some causes for the enlargement include
congenital defects, surgical procedures on the lung, or an infection (Ferrara, 2011). The
disease process itself centers around inflammatory injury to the lung due to abnormal
immune response to products like the toxic particles in tobacco smoke, inhalation of
environmental particulates, or occupational exposure to biomass fuel products in poorly
ventilated areas. A poor immune response causes the small air-exchange spaces in the
lungs to expand and combine into larger, dysfunctional airspaces. This results in a loss of
function, a loss of lung elasticity, an increase in hyperinflation, and ultimately, a
reduction of airflow in the lungs (Ferrara, 2011). There are several types of emphysema,
such as panacinar emphysema and centrilobular emphysema, but each form displays the
same destructive patterns (Ferrara, 2011).
Bronchitis is the inflammation of the bronchial tubes. The bronchial walls
become permanently inflamed or thickened. This creates a cough that produces mucus or
phlegm. Chronic bronchitis is a progressive disease that is defined by coughing at least
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one time a day for 3 months. Complications from chronic bronchitis include asthma,
bronchectasis, cystic fibrosis, tuberculosis, and sinusitis.
General Risk Factors
Risk factors for COPD are outdoor air pollution and indoor air pollution, such as
occupational dust and particulate irritants and chemical vapors and fumes (GOLD, 2010).
Biomass fuels are a major contributor to COPD among nonsmoking women in countries
like Africa and Asia, as well (World Health Organization, 2011). Individuals with
frequent lower respiratory infections during childhood are at risk for COPD (GOLD,
2010; MedlinePlus, 2011). Genetics is also a factor in the rare cases of individuals who
develop emphysema due to a lack of the protein alpha-1-antitrypsin (MedlinePlus, 2011).
The metabolic and physiological changes of aging can influence efficacy and
safety. In order patients, the high prevalence of comorbidities such as cardiovascular
disease and osteoporosis can reduce tolerance to COPD therapy. (Malipatil & McDonald,
2009). In the Burden of Obstructive Lung Disease initiative, the prevalence of COPD
GOLD Stage II or higher across 12 countries was 11.8% for men and 8.5% for women
(Imperial College London, n.d.; Nazir & Erbland, 2009). Results from this study showed
that disease prevalence increases with age. Less than 5% of all persons aged 40 to 49 had
COPD, but the incidence increased 19% to 47% and 6% to 33% in men and women,
respectively, for those aged 70 and over (Nazir & Erbland, 2009).
Another risk factor is exposure to certain environmental conditions during
childhood. Depending on the type of pollutant and the amount inhaled, children may
have the same level of risk as smokers (Ferrara, 2011). In addition, maternal smoking has
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been associated with the development of respiratory diseases (including COPD) in adults
(Ferrara, 2011).
COPD rates in the United States are inversely proportional to socioeconomic
status, with blue-collar workers exhibiting higher degrees of mortality and morbidity
rates than white-collar workers (Ferrara, 2011). Individuals who work on a farm are
constantly exposed to dust and are two to three times more likely to develop COPD than
non-farm workers. Coal miners also have an increased risk due to their working
environment (Ferrara, 2011). These same disparities are apparent when comparing
education and income (Ferrara, 2011). The risk of developing COPD during adulthood
may be linked to lower socioeconomic status during childhood, resulting from to
exposure to outdoor and indoor pollution (Nazir & Erbland, 2009).
Genetic studies have looked at the association of polymorphism and COPD. A
meta-analysis study on 20 polymorphisms in 12 candidate genes showed that many genes
were not linked to COPD. However, the study populations included in the sample
influenced this result (Cosio & Agusti, 2010). In addition, a study linking the C-reactive
protein gene to COPD has been inconclusive. Therefore, evidence linking genetic
inheritance and COPD is currently inconclusive, and further research is needed (Cosio &
Agusti, 2010).
Symptoms
Symptoms of COPD include abnormal sputum (a mixture of mucus and saliva the
airway), breathlessness, and a chronic cough. Other symptoms include mucus produced
when coughing, shortness of breath (dyspnea) that worsens even with minimal activity,
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presentation of respiratory infections, and wheezing (MedlinePlus, 2011). Daily activities
like walking upstairs can become difficult as the disease worsens (World Health
Organization, 2011). Other problems include increased anterior and posterior chest
diameter—AKA “barrel chest”—caused by air trapping; cyanosis; nail clubbing: and the
use of accessory muscles when breathing (Ferrara, 2011). COPD patients may not
experience all of these symptoms. For example, in one study 43% of patients did not
produce sputum (Lynes, 2010; Zieliñski, Bednarek, & Group, 2001). Since COPD is
progressive, the disease is often undetected; patients are not aware that they are sick. The
first indication of COPD may be when the symptoms worsen; increased quantities of
sputum, sputum purulence, and shortness of breath (dyspnea) are signs that the patient
has an exacerbation at a more advanced stage of the disease (Albertson, Louie, & Chan,
2010; MedlinePlus, 2011; Stoloff, 2011). More specifically, these are signs of acute
exacerbations of chronic bronchitis (Albertson et al., 2010; Lynes, 2010; MedlinePlus,
2011). However, COPD is a heterogeneous disease and can be difficult to diagnosis.
Exacerbation is an acute action resulting in a deviation in the individual’s
dyspnea, cough, or sputum production from the norm and requires a change in regular
treatment (Garvey, 2011; Nazir & Erbland, 2009). Exacerbations of COPD decrease
QoL and lung function (Garvey, 2011). These exacerbations are interconnected and are
associated with increased morbidity, increased comorbidities, decreased physical health,
and increased chances of premature mortality (Glaab, Vogelmeier, & Buhl, 2010).
However, comparing clinical symptoms of different patients can be challenging, because
there are no standard definitions of exacerbations (Glaab, Vogelmeier, & Buhl, 2010;

27
Nazir & Erbland, 2009). In addition, exacerbations can be underreported due to recall and
selective bias by patients (Glaab et al., 2010). Contributors to acute exacerbations include
exposure to air pollution from particulates of diesel, sulfur dioxide, ozone, and nitrogen
(Nazir & Erbland, 2009). Other risk factors include age, decreases in FEV1, lung
infection, and high frequencies of past exacerbations (Albertson et al., 2010; Nazir &
Erbland, 2009). Seventy-five percent of cases of acute exacerbations are caused by viral,
bacterial, or mixed viral-bacterial changes (Albertson et al., 2010). Research indicates
that these exacerbations are semirandom. This means that the exacerbations are
unpredictable but tend to cluster in time. For example, after a patient is subject to a first
exacerbation, then the chances of a second exacerbation are greatly increased (Cosio &
Agusti, 2010).
Methods for Diagnosis
Due to the wide range of comorbidities and the progressive nature of COPD,
researchers have focused on early diagnosis, prevention, and treatment. There are
invasive approaches to determine airway inflammation, such as bronchoscopy and
brancholveolar lavage, but these have been complemented by or replaced by the
noninvasive method of induced sputum analysis (more information in the next section).
However, the limitations of the induced sputum method have led researchers to consider
alternative methods, such as EBC sampling. Current methods for testing airway
inflammation include spirometry to analyze lung function and sputum induction to
determine airway inflammation.
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Spirometry is performed by having the patient blow into a handheld device that
measures lung capacity. Trained medical personnel can interpret the test results directly
without the patient having to exercise, draw blood, or be exposed to radiation
(MedlinePlus, 2011). This is one of the most important tests for determining COPD
severity levels; it is both accurate and reliable (Garvey, 2011). Even though the method
is considered the gold standard for measuring COPD progression, the procedure is
underused or used inconsistently in the clinical setting (Stoloff, 2011). For example,
several studies assessed the use of spirometry in patients hospitalized and then discharged
with a diagnosis of COPD (Stoloff, 2011). Only 31% of these patients were tested using
spirometry over an 8-year period (Stoloff, 2011). Studies in Germany, Switzerland, and
Denmark found that spirometry testing was underutilized when diagnosing COPD,
leading to the underreporting of the disease (Jochmann et al., 2010; Smidth et al., 2012).
In addition, other countries with good healthcare such as the United States, Spain, and
Italy, also reported under usage of spirometry (Spyratos et al., 2012).
Spirometry is one of the most important analysis for the diagnoses of COPD. The
GOLD standard suggests a bronchodilator rate of FEV1/FVC < 70% diagnostic for
COPD. A limitation is that the FEV1/FVC ratio naturally declines with age, and using a
fixed ratio increases the risk of over-diagnosing COPD in the elderly. Factors
contributing to over-diagnosis include reduced perception of airflow, tendency to
attribute symptoms to aging process, and lack of spirometric testing (Malipatil &
McDonald, 2009). In clinical practice this risk is offset by underdiagnoses in older
people (Malipatil & McDonald, 2009).
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Sputum induction is a primary analytic tool for the study of airway inflammation
(Djukanovic, 2000). Sputum culture is used to detect and identify bacteria or fungi that
are affecting the lungs or breathing passages (WebMD, 2012; 2011). One of the benefits
of using induced sputum is the safety of the method; it is easy to use given time but
depends on the severity of the disease and the patient’s ability to produce sputum at home
(Djukanovic, 2000; Holz et al., 2008). A second benefit is that sputum induction does not
require expensive equipment and testing is generally reimbursed by insurance (Holz et
al., 2008). Third, sputum induction results in a more representative sample of several
proximal airways than other methods (Djukanovic, 2000). Limitations include high
levels of thick mucus in unprocessed sputum (Djukanovic, 2000). Samples are of lower
quality of induced sputum and smear slide samples provide only semiquantitative
information (Holz et al., 2008). The induction process of sputum is not suited to the
outpatient setting because the method is labor intensive, depending on the patient ability
to produce sputum, and the method is time consuming (Holz et al., 2008).
Spirometry is the current benchmark for determining COPD, and sputum
induction can identify bacteria and/ or fungi affecting the lungs. However, there are
limitations to both methods (Tables 5-6). A promising area of research is using EBC to
differentiate between different respiratory diseases and between phenotypes of the same
disease. Two studies published in 2011 use EBC to differentiate COPD patients who
were smokers from those who were nonsmokers. An eNose was used in both studies to
analyze EBC from patients. One study was able to differentiate between asthmatic
patients and those with COPD but unable to identify different stages of COPD by EBC
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alone (Holz, Zesiger, Lavaue-Mokhtari, Schuchardt, & Hohfeld, 2011). This study, which
had a small sample size of 14 patients, concluded that evaluating exhaled breath profiles
by eNose has the potential to become a widely used noninvasive diagnostic tool. In the
same year another study, using 100 patients, was able to differentiate between COPD and
non-COPD patients. The study conducted in the Netherlands used 100 patients, a Tedlar
bag sample collection system, and an eNose (Fens et al., 2011; Fens, Roldaan,
Zwinderman, Bel, & Sterk, 2011). However the conclusion also mentioned that a more
sensitive method and further research is necessary to show phenotypic differences (Fens
et al., 2011; Fens, Roldaan, Zwinderman, Bel, & Sterk, 2011). Both 2011 studies state
that EBC is a promising method for noninvasive analysis of some respiratory diseases.
Other researchers have used a wide variety of tools to diagnose EBC—eNoses with
varying sensitivities, ion mobility spectrometers, differential mobility spectrometry, GCMS, and gas sensory array technology, to name a few. With the exception of an eNose
application published in 2009, none have been able to uncover the heterogeneity of
COPD. The 2009 study (Velásquez, Durán, Gualdron, Rodriguez, & Manjarres, 2009)
distinguished between phenotypes, but the results were subjective because the
classification of phenotypes was done by a personal physician and were not reproducible.
Exhaled Breath Condensate
To date, researchers have identified more than 3,500 components (mixtures of
gases and volatile organic compounds) in exhaled breath (Popov, 2011). Almost half of
the volatile organic compounds originate from within the body, and approximately 200
trace compounds can be detected and quantified in an average human breath (Popov,
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2011). The compounds can vary due to diet or disease. One of the most well-known
examples of breath analysis is ethanol analysis, used to check for alcohol consumption
levels. Other successful clinical applications include linking NO levels to asthma and
linking carbon monoxide to oxidative stress (Popov, 2011).
Using EBC for collecting and analyzing biomarkers has several advantages—ease
of use, noninvasiveness, the possibility of repeated sampling, and suitability for use with
children and patients with severe disease (Koczulla et al., 2009). In addition, samples can
be collected in a portable device home (Koczulla et al., 2009).
One limitation of using EBC for COPD determination is its variability in
statistical analysis. There are several algorithms used to draw correlations between EBC
and respiratory diseases—specifically, asthma and COPD. The results are more or less
favorable depending on the algorithm used. Therefore, researchers tend to use algorithms
that portray the data in the best possible manner. Standardization is necessary to be able
to compare data from one study to another. A second limitation is that there is no
standard or accepted method for EBC analysis. Several techniques have been used,
including various eNoses, mass spectrometers, combination GC-MS, ion mass
spectrometers (IMS), proton transfer reaction–mass spectrometers (PTR-MS), and gas
sensor arrays. No one method out-performs the others, although PTR-MS and IMS show
promise. The limitation is that comparing data with different types of diagnostic devices
is challenging without standardized methods. This is further complicated when
comparing different diagnostic equipment with different algorithms. A third limitation is
the lack of standardization of a sampling technique. Collection techniques range from
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having the patient breathe one time into a Tedlar bag to sampling using PTR-MS, where
the PTR-MS and the patient must be present at the same time and breath is collected over
a given period of time, such as ten minutes. The difficulty is in knowing which part of
the lung (lower, middle, or upper regions) the air is coming from; breath profiles will
vary depending on where the exhaled air originates. A fourth limitation of the current
literature is that many studies start with known diseased and healthy populations.
Because of all these variations in sample selection, sampling technique, and analysis,
cross–research validation is challenging. However, the initial results, regardless of
algorithm, diagnostic analysis, or sampling technique, show promise that EBC might be
able to diagnose severity in COPD patients. Tables 5, 6, and 7 list the strengths and
weaknesses of the three most widely used diagnostic techniques.
Table 5
Spirometry Strengths and Weaknesses
Strengths
Accurate
Reliable
Noninvasive

Weaknesses
Underused in clinical setting
Used inconsistently in clinical setting
Need trained medical personnel to interpret
Results subjective

Note. Adapted from Holz et al. (2008). Assessing airway inflammation in clinical practice—experience with spontaneous sputum
analysis. Biomedical Central Pulmonary Medicine, 8, 5. doi: 10.1186/1471-2466-8-5
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Table 6
Sputum Induction Strengths and Weaknesses
Strengths
Safety
Ease of use
Can be done at home
Does not require a lot of equipment

Weaknesses
Unprocessed sputum contains abundant and
thick mucus
Provides only semiquantitative information
Labor intensive for quantitative cell count
Time consuming and not suited for outpatients

Note. Adapted from Holz et al. (2008). Assessing airway inflammation in clinical practice - experience with spontaneous sputum
analysis. Biomedical Central Pulmonary Medicine, 8, 5. doi: 10.1186/1471-2466-8-5

Table 7
Exhaled Breath Strengths and Weaknesses
Strengths
Weaknesses
Noninvasive
No universal sampling preparation standard
Suited for outpatients
Several algorithms
No trained staff required
Multiple diagnostic machines
Easy to use
Not sensitive enough
Repeated sampling —Do not run out of
air
Note. Adapted from Holz et al.. (2008). Assessing airway inflammation in clinical practice —experience with spontaneous sputum
analysis. Biomedical Central Pulmonary Medicine, 8, 5. doi: 10.1186/1471-2466-8-5

Because each of these techniques has practical limitations, researchers are continuing to
test different methods and compounds in EBC in relation to COPD. One compound of
particular interest is NO, because NO is linked to airway inflammation in asthma.
Considering that airway inflammation is found in all stages of COPD, NO may be a
marker for airway inflammation in COPD.
Nitric Oxide: General Overview
NO is associated with airway inflammation in asthma and is key to evaluating,
managing, and predicting outcomes in asthma patients (Beg et al., 2009). NO may have a
positive association with COPD, considering that inflammation of the airway is found in
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all forms of COPD (Beg et al., 2009). Inflammation may be present in the airways, lungs,
and pulmonary blood vessels. FENO is a noninvasive, time-saving, highly reproducible,
and cost effective method for assessing inflammation (Bazeghi et al., 2011; Beg et al.,
2009). This study will investigate eNO as a potential marker for airway inflammation in
COPD.
Current research focuses on analyzing NO, eNO, FENO, NO in the alveolar
region (CalvNO) and NO in the bronchial region (JawNO). NO is the most basic form
and can be separated into alveolar and bronchial. Most past research focuses on eNO or
FENO; however, alveolar and bronchial NO studies are increasing.
NO readings are reproducible from one day to the next in healthy individuals and
in patients with stable COPD (Rouhos et al., 2011). In addition, comparisons of NO
exhaled in one breath and EBC at varying flow rates found no significant difference due
to sampling technique (Lehouck et al., 2010). NO levels increase during periods of
exacerbation (Agustí, Villaverde, Togores, & Bosch, 1999; Bhowmik et al., 2005; Liu et
al., 2007). Other factors that affect NO levels in EBC include suffering from the
common cold, eating NO-rich foods, working at certain occupations, and smoking
tobacco. The amount of NO depends upon the frequency, duration, and the time at which
the NO readings were taken in relation to the above factors. In addition, NO
measurements may differ significantly depending on the diagnostic device (Borrill et al.,
2006; Korn, Telke, Kornmann, & Buhl, 2010).
Research has shown that NO levels differ between healthy smokers and smokers
diagnosed with COPD. However, data was inconclusive when analyzing the effects of
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smoking in the following subgroups of COPD patients: smokers, ex-smokers and healthy
COPD patients (Beg et al., 2009; Lehouck et al., 2010). One study demonstrated that
FENO levels were elevated in COPD patients compared to controls (56 +/- 28.01 vs.
22.00 +/- 6.69, p = 0.0001; Beg et al., 2009). However, the sample size was low, with a
total of 14 COPD patients included in the sample. Other factors which may have affected
the study were that (1) all participants were male; (2) current smokers were included in
both the COPD and the control groups; and (3) patients using steroids were included (Beg
et al., 2009). However, another study found that eNO is significantly higher in EBC of
chronic smokers than in nonsmokers (Liu et al., 2007). COPD-diagnosed individuals
contained higher eNO levels in their breath than healthy controls (9.8 +/- 0.7 vs. 5.5 +/0.4, p < 0.0005; Liu et al., 2007). In addition, when comparing nonsmoking COPD
patients with ex-smokers, COPD patients registered higher eNO levels as well (9.2 +/1.2 vs. 5.7 +/- 0.5, p = 0.002; Liu et al., 2007). Another study that examined NO levels in
smokers, ex-smokers, and nonsmoker COPD patients showed no difference in eNO levels
(Lehouck et al., 2010). Comparison of healthy ex-smokers and healthy smokers yielded
similar results (3.3 +/- 0.6 vs. 3.1 +/- 0.7). COPD smokers had slightly higher eNO levels
(2.2 +/- 0.6 vs. 2.6 +/- 0.7; Lehouck et al., 2010) than COPD ex-smokers. This study
accounted for confounding variables such as gender, current smoking behavior, body
mass index (BMI), and age. However, the sample size of COPD patients was small (22
participants).
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Nitric Oxide: Association Between COPD and Nitric Oxide
One study tested 91 COPD patients with emphysema and chronic bronchitis to
determine if there was a relationship between FENO and COPD (Bazeghi et al., 2011).
The main focus of this study was to examine flow rates of NO. All patients had a
smoking history and BMI was recorded. BMI readings were taken. Patients were
allowed to take prescribed medications up to midnight the day before the testing;
however, oral corticosteroid therapy was stopped four weeks prior to the exam (Bazeghi
et al., 2011). A potential confounder was the inclusion of patients with exacerbations;
studies have shown higher eNO readings during exacerbation (Bhowmik et al., 2005).
NO levels in patients with severe emphysema were calculated for airway wall
concentration (Caw); alveolar concentration of NO (Calv); and D, the diffusing capacity
of NO (DawNO). There were no significant differences among FENO levels and any of
these measurements, as proven by the following p-values; p = 0.15, p = 0.22, and p=
0.21 respectively (Bazeghi et al., 2011). Results for a study on FENO levels and chronic
bronchitis results were not significant, either: Caw (p = 0.31), Calv (p = 0.58), and D (p =
0.56; Bazeghi et al., 2011).
A second study with 151 patients—84 with COPD (55 ex-smokers and 29
smokers) and 67 healthy controls (28 smokers and 39 smokers)—concluded that the tests
were unable to differentiate between patients with and without COPD (Lehouck et al.,
2010). Comparison of healthy ex-smokers and healthy smokers yielded similar results
(3.3 +/- 0.6 vs. 3.1 +/- 0.7). In a comparison of COPD ex-smokers and COPD smokers,
COPD smokers had slightly higher results (2.2 +/- 0.6 vs. 2.6 +/- 0.7; Lehouck et al.,
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2010). This study accounted for confounding variables such as gender, current smoking
behavior, BMI, and age. A potential weakness was that the sample size of COPD patients
was small (22 participants). A study of 16 COPD subjects and 8 healthy nonsmokers
found that there was no difference between eNO readings in the two groups (Rutgers et
al., 1999). NO excretion rates between COPD and healthy patients were observed. NO
correlated with sputum eosinophils in patients with COPD (p = 0.009) but not with
healthy controls (Rutgers et al., 1999). A study comparing both online and offline
sampling measurements for eNO found that the sampling methods did not affect eNO
levels (Deykin, Massaro, Drazen, & Israel, 2002). This study tested 28 healthy subjects
and 34 asthma patients using different NO offline or online sampling techniques (p =
0.25 to 0.98; Deykin et al., 2002). Despite several studies unable to identify a correlation
between NO and COPD, there were two studies that reported positive results. A study
using 81 patients (18 nonsmokers, 16 smokers, 47 COPD) found a correlation between
NO and COPD (Brindicci et al., 2005). There was a significant negative correlation
between CalvNO, and FEV1 against COPD patients and normal healthy smokers (r = 0.6, p =< 0.0001). Measures of the diffusion of NO in airways (DawNO) were elevated in
smokers compared to COPD patients. This results in a weak negative correlation between
DawNO and FEV1 in all COPD patients and smoking subjects (r = -0.4, p = 0.006)
(Brindicci et al., 2005). This study had a small sample size of COPD patients (n = 14).
There was no mention of confounders (such as gender, medication, or age) affecting the
sample population. NO readings were taken on a standard chemiluminescence analyzer
(Brindicci et al., 2005).
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A study with 13 current smokers with COPD, 8 ex-smokers with COPD, 12
patients with unstable COPD, and 10 smokers with chronic bronchitis found that the
correlation between these types of COPD patients was negative for NO levels and lung
function as defined by FEV1 (Maziak et al., 1998). The study found that eNO levels in
unstable COPD was higher than in COPD ex-smokers, COPD current smokers, and
chronic bronchitis groups (12.7 +/- 1.5, < 0.01). Unstable COPD was defined by having
exacerbations and/or severe COPD (Maziak et al., 1998). Exhaled NO levels more were
elevated in COPD smokers than in individuals who smoked and had chronic bronchitis
(4.3 +/- 0.5 vs. 2.5 +/- 0.5, p < 0.05) and higher in ex-smoking COPD patients (p < 0.01)
(Maziak et al., 1998). However, eNO levels demonstrated a negative association with
FEV1 (r = -0.6, p =< 0.001; Maziak et al., 1998). A weakness was that the GOLD
standard was not used to categorize COPD patients, as it has been in more recent studies
(Maziak 1998).
Nitric Oxide: COPD and Severity
A study using 81 patients (18 nonsmokers, 16 smokers, 47 COPD) measured
forced expiratory NO at several expired flows and found that alveolar FENO is increased
and has a positive correlation with COPD and GOLD severity levels (Brindicci et al.,
2005). The CalvNO increase was significant in COPD patients, resulting in a positive
correlation between CalvNO and FEV1 in COPD patients and normal healthy smokers
(Brindicci et al., 2005). JawNO levels were lower in smokers than in healthy nonsmoking
controls. Results for nonsmokers and GOLD Stage I-II and GOLD Stage III-IV were
respectively (630.3 +/- 417.7 vs. 716.2 +/- 141.7 vs. 609.4 +/- 275.0). However, levels of
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DawNO increased in COPD patients compared with smokers and controls (GOLD Stage
I-II at 15.7 +/- 5.1; GOLD Stage III-IV at 25.0 +/- 5.0; nonsmokers (11.0 +/- 2.5); and
smokers (11.6 +/- 3.2; Brindicci et al., 2005). A weak negative correlation was found
between DawNO and FEV across all COPD and smoking subjects (r = -0.4, p = 0.006;
Brindicci et al., 2005).
Conversely, a cross-sectional study that tested 64 patients (25 with bronchial
asthma, 14 with COPD and 25 normal) found that in COPD patients, there was a negative
correlation between FEV1/FVC ratio and the level of FENO (Beg et al., 2009). COPD
patients had higher FENO levels than controls (56.54 +/- 28.01 vs. 22.00 +/- 6.69, p =
0.0001; Beg et al., 2009). A study of 43 patients with COPD found a negative correlation
between NO and FEV1 (r = -0.6, p < 0.001; Maziak et al., 1998). In addition, a casecontrol study with 151 patients, 84 with COPD (55 ex-smokers and 29 smokers) and 67
healthy controls (28 smokers and 39 smokers) found that there was no association
between NO (FENO, CalvNO, JawNO) and COPD severity (Lehouck et al., 2010). A
multivariate analysis found that gender, age, BMI, GOLD stage, and corticosteroid use
had no effect on the study. Rather, CalvNO was the only variable that affected the
association (p = 0.0115; Lehouck et al., 2010). Therefore, based on current literature, the
association between NO and COPD severity is inconclusive.
Occupational Exposure
One of research aims of this dissertation was to determine if the association
between eNO and COPD is affected by occupational exposure. Several studies have
reported association between eNO exposure and asthma (Demange, Bohadana, Massin, &
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Wild, 2009; Lund, Oksne, Hamre, & Kongerud, 2000; Tossa et al., 2009; Tossa et al.,
2010). Some studies have examined the relationship between eNO and occupational
exposure without reference to a specific disease outcome (Kim et al., 2003; Ulvestad et
al., 2001). To my knowledge, no studies to date have explored whether the role of
occupation modifies the association between eNO and COPD. Kim et al. (2003)
examined workers exposed to metal-containing fine particles from boilermakers. The
study found that eNO concentrations decreased over a 5-day period of when not exposed
to the particles, with a -5.5 parts per billion (ppb) mean change (95% CI: -8.8, -2.1). In
addition, the mean change in FEV1 and FVC exhibited the same trend for the same time
period, -1.7 L (95% CI: -0.24, -0.09) and -0.14 L (95% CI:-0.23, -0.04) for FEV1 and
FVC, respectively (Kim et al., 2003). One reason for the decrease in eNO was that the
study environment contained high levels of transition metals such as iron, nickel, and
vanadium (Kim et al., 2003), whereas other studies contained a larger amount of ambient
air (Demange et al., 2009; Tossa et al., 2009; Tossa et al., 2010)
The studies that demonstrated an increase in eNO with occupational exposure
were conducted in a wide range of environments. Most of these studies examined the
effects of eNO and occupation on asthmatics. Exhaled NO is a known biomarker for
airway inflammation in asthmatics, and different types of occupational exposures have
been known to affect eNO readings in asthmatics. Workers are exposed to a variety of
factors that can affect airway hyperresponsiveness and lead to increased FENO levels
(Demange et al., 2009). A study of 351 bakers and hairdresser apprentices showed an
increase in FENO associated with bronchial hyperresponsiveness (OR 2.00, 95% CI: 1.21
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– 3.32; Tossa et al., 2010). Indoor and outdoor construction workers showed significant
differences in FENO (8.4 +/- 1.09 vs. 5.6 +/- 1.07, p = 0.001; Ulvestad et al., 2001).
Indoor lifeguards showed elevated FENO levels compared to outdoor lifeguards
(Demange et al., 2009).
Based on these studies, it appears that eNO levels change depending on the type,
duration, and concentration of exposure. If occupation modifies of the association
between eNO and COPD, then a public health professional using eNO as a biomarker for
COPD might misdiagnose a person who works in a high-risk occupation as having COPD
when in fact the eNO is related to the job and not the disease. The increase in eNO might
be due to an increase in airway inflammation as a result of asthma. Another possibility is
that eNO concentration, FEV1, and FVC readings may actually decrease over time,
giving a false-positive reading when diagnosing COPD (Kim et al., 2003). Therefore,
occupation must be taken into consideration when analyzing eNO and COPD
associations otherwise eNO occupational exposure may confound results.
Confounders
Potential confounders are age, gender, medications, race, body mass index,
tobacco smoking, having other respiratory illnesses, eating and drinking nitrogen-rich
foods and beverages, exercising, the presence of other respiratory illnesses, and tobacco
smoking. Age: COPD is usually detected in persons aged 40 and over because of the
disease’s progressive nature. Younger individuals usually have less airway inflammation
damage. As the disease progresses with age, so does severity. Therefore, age becomes a
potential confounder if age is not matched in the sample population. Gender: In some

42
populations, COPD incidence in women (5.4 95% CI: 5.3-5.6) is higher than in men (2.8
95% CI: 2.7-2.9; Bang et al., 2009). Exhaled NO in the forms of DawNO and CalvNO
showed a significant effect of eNO when compared to COPD (p = 0.049 and 0.048
respectively; Bazeghi et al., 2011). Therefore, gender must be matched against controls to
ensure a representative sample. Race: Different races will have varying degrees of COPD
and COPD severity based on socioeconomics, lifestyle, and occupation. Exercise and
BMI: Exercising and BMI may confound results as well. Medications: Corticosteroids
will reduce the NO levels in the body and help alleviate airway inflammation. One study
found that patients taking inhaled steroids had significantly higher eNO levels than those
taking little or none (8.2 +/- 1.2 vs. 5 +/- 0.4, p =< 0.05; Maziak et al., 1998). Therefore,
all subjects must refrain from taking corticosteroids before testing or the results may be
skewed. Nitrogen-rich foods and beverages: Consumption will cause nitrogen levels to
increase during testing, so the recommendation is that individuals do not eat or drink
several hours before testing. Other respiratory diseases: Having a cold or other
respiratory disease such as asthma may affect eNO readings as well. Exacerbations have
been linked to higher exhaled nitrogen oxide readings (Agustí et al., 1999). Therefore,
patients must document the frequency and type of exacerbation. Smoking: Studies have
demonstrated that eNO levels differ between smokers, ex-smokers, patients with COPD
who smoke and former COPD smokers (Beg et al., 2009; Brindicci et al., 2005; Liu et
al., 2007). Therefore it is important to match cases and controls for the study and
document smoking habits prior to testing.

43
Summary
In summary, current research is inconclusive on the association between eNO and
COPD (emphysema and chronic bronchitis) and eNO and COPD severity. One of the
main limitations of research to date has been the small sample sizes of COPD patients
included in the studies. Therefore, this study included a larger sample size from past
studies and tested the associations between eNO and COPD (emphysema and chronic
bronchitis), Exhaled NO and COPD severity, and occupation and COPD. The
methodology to conduct the research is explained in detail in Chapter 3.
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Chapter 3: Research Method
Introduction
Airway inflammation is found in all forms of COPD. NO and NO derivatives are
known markers of airway inflammation present in EBC. Research has shown a
correlation between eNO and asthma; however, association between NO derivatives,
airway inflammation, and COPD severity is inconclusive. In this study, I analyzed the
association between eNO and COPD to determine if eNO could be used as a biomarker
for COPD diagnosis.
Current noninvasive techniques such as spirometry often result in under- or
misdiagnosis (Jochmann et al., 2010; Lehouck et al., 2010; Smidth et al., 2012; Spyratos
et al., 2012). One major limitation of using spirometry in outpatient settings is that
training is lacking, and the equipment requires frequent calibration. Moreover, general
physicians are not trained to read and interpret results consistently (Holz et al., 2008).
The findings from this study could potentially lead to the development of
noninvasive methods and diagnostic tools to diagnose COPD in outpatient settings that
will not have the same limitations as spirometry. This may result in early diagnosis, better
management, and lower prevalence of late-stage COPD, thereby decreasing
complications and mortality rates. Because of ease of use, more primary care physicians
are likely to adopt and use it routinely in clinical settings.
In this study, I used NHANES 2007 to 2010 data to test three hypotheses. The
first hypothesis posited an association between eNO and COPD, defined as a patient
having emphysema and/or chronic bronchitis. The second hypothesis posited an
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association between eNO and COPD severity, as defined by the GOLD standards, which
recognize four stages of severity defined by increasing levels of airway inflammation.
The third hypothesis posited that a person’s occupation can modify the association
between COPD and eNO. Environmental factors associated with employment are often
under- or not reported in literature examining the association between eNO and COPD
(Bazeghi et al., 2011; Brindicci et al., 2005; Lehouck et al., 2010; Liu et al., 2007).
The Center for Disease Control and Prevention’s (CDC) National Center for
Health Statistics (NCHS) conducts the National Health and Nutrition Examination
Survey (NHANES), an annual study that combines interviews and physical examinations
of over 5,000 individuals in the United States (CDC, 2013a). The sample is representative
of the United States population, and the data are publicly available on the CDC website
(www.cdc.gov/nhanes) for anyone to use and analyze.
Research Design and Approach
This cross-sectional analysis used NHANES data from 2007-2008 and 2009-2010
to test the association between eNO and COPD. This research design was different from
other research studies in several aspects. First, most studies evaluating the relationship
between eNO and COPD have been small, clinical studies (Bazeghi et al., 2011;Beg et
al., 2009; Liu et al., 2007; Robbins et al., 1996; Rutgers et al., 1999). This study used a
large population-based data source; hence, the findings are generalizable to a broader
population. Second, most previous research analyzed either the presence of COPD
(yes/no) or COPD severity (a matter of degree; Bazeghi et al., 2011; Beg et al., 2009;
Bessa et al., 2011; Bhowmik et al., 2005); this study investigated both. Finally, this is the
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first study to my knowledge that has investigated the association between eNO and
COPD by occupation.
Data from this study were abstracted from the examination files listed in Tables 8
to 16. The total sample size for NHANES 2007 to 2010 was 20,686 (10,149 for 2007–
2008 and 10,537 for 2009–2010). The sample was restricted to adults 30 years and older,
because COPD is a slow-progressing disease that manifests later in life. The typical cutoff is 40 years old, because prevalence increases with age. However, this study included
the 30-year cut-off because COPD can be present in younger patients and as shown in the
results section, the 30 to 39-year-old category indeed had a relatively high prevalence
(3.6%) of COPD.
NHANES Data Set
The NHANES program began in the 1960s and focuses on different populations
and health topics. The program became continuous in 1999. NHANES is an ongoing,
stratified, multistage probability program of studies that examines 5,000 civilian,
noninstitutionalized adults and children in the United States. Fifteen counties/ locations
are visited annually where participants are interviewed, physical examinations conducted,
and lab tests completed. Interviews are conducted to gather demographic, socioeconomic,
dietary, and health-related information (CDC, 2013a). The physical examinations consist
of medical, dental, and physiological measurements (CDC, 2013a). The final component
is laboratory testing for blood and urine.
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Data Collection
NHANES data were collected from interviews, physical examinations, and
laboratory tests. The NHANES study team consisted of a physician, medical and health
technicians, and dietary and health interviewers. Health interviews were conducted in the
homes of respondents by a Screener, Sample Person, and Family Interviewer. Data were
recorded using the Blaise computer-assisted personal interview (CAPI; CDC, 2013a).
Physical examinations were performed in equipped mobile examination centers (MEC)
that visited each location in the country. All participants visited the MEC physician for
exams that can take up to 3 hours each. The laboratory staff consisted of medical
technologists and phlebotomists trained by the American Society for Clinical Pathologists
or other organizations in standard laboratory procedures (CDC, 2013a). The medical
technologists all held baccalaureate degrees (CDC, 2013a). The phlebotomist had
completed training in pediatric techniques. All MEC staff were trained in safety, subject
privacy and confidentiality, and cardiopulmonary resuscitation.
NHANES uses a mostly paperless system by incorporating touch-sensitive
computer screens, an audio computer-assisted self-interview system, CAPI, computerassisted self-interviews, face-to-face interviews, and on-site electronic questionnaires
(CDC, 2013a). The MECs used automated collection procedures. Laboratory
components were recorded directly into a computer database. Access to NHANES data is
free to the public.
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Constructing Weights
Sampling data combining two or more 2-year data sets must be weighted to
ensure that the sum of the weights matches the survey population (CDC, 2013a). The
weights used in the analysis were the examination weight (variable name: WTMEC2YR)
and the 4-year (2007 to 2010) weights that were constructed using the following formula
(CDC, 2013a).
If addsrvyr in (5, 6) then MEC4YR = ½* WTMEC2YR; /*for 2007 to 2010
*SDDSRVYR is the survey cycle variable. In this case 5 = 2007 to 2008 and 6 =
2009 to 2010. (CDC, 2013a)
Sample Size Calculation
The sample size of 1,001 was calculated using the Stata Powerlog power analysis
from the UCLA Statistical Consulting Group (UCLA Statistical Consulting Group 2013).
COPD is the binary dependent variable. Subjects will have COPD and controls will not.
Exhaled nitrogen oxide was a categorical independent variable measured in quartiles and
tested against the binary variable COPD. The calculation assumes that p1 = 0.08 and p2 =
0.11 (OR = 1.42) for the proportion of subjects with both exhaled nitric oxide and COPD
data. P1 (0.08) was calculated by dividing the number of confirmed physician diagnosed
COPD cases (n = 805) by the total sample population (n = 10,214). P2 (0.11) was
calculated by dividing pre-bronchodilator COPD cases (n = 1,160) by the total number of
subjects (n = 10,214). The total sample size of 1,001 was calculated with an alpha of
0.05 and a power of 0.90.
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Study Variables
Dependent Variables: Chronic Pulmonary Obstructive Disease (COPD) and COPD
Severity
In both the 2007–2008 and the 2009–2010 datasets, COPD (emphysema and
chronic bronchitis) was determined by these two questions: “Ever told you had
emphysema?” and ”ever told you had chronic bronchitis?” (see Table 10; CDC, 2013b,
2013c). The binary variable was formed by individuals with positive responses to one or
more of these questions that were coded as 1 = yes. Individuals who responded negatively
to both questions did not have COPD and were coded 0 = no to form a binary variable.
COPD severity was calculated using individual prebronchodilator spirometry data
for the COPD population from NHANES 2007 to 2010, converted from milliliters to
liters. A ratio was calculated by dividing FEV1 by FVC. Observed values less than 70%
were divided by predicted values and aligned to the GOLD standard to determine severity
as Stage I, II, III, or IV for analysis. All individuals with a predicted value of FEV1/FVC
greater than or equal to 80% were placed in Stage I and labeled as mild. Individuals with
a ratio between less than or equal to 80% and greater than or equal to 50% were defined
as Stage II and labeled as moderate. Stage III individuals had ratios less than 50% were
labeled as severe/very severe. Since there were few observations for Stage III and Stage
IV, data for these two categories were combined into one category, Stage III.
Observed baseline measurements for FEV1 were provided in NHANES 2007 to
2010 datasets. Predicted values were calculated by dividing the observed FEV1 value by
the predicted FEV1 value estimated for an individual of similar age, height, gender, and
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race, using gender- and race-specific reference equations (Hankinson, Odencrantz, &
Fedan, 1999). A correction factor of 0.88 was applied for race/ethnicity category listed as
“other.” (Hankinson et al., 1999).
Independent Variable: Exhaled Nitric Oxide
FENO readings, measured in ppb, were taken during the physical examinations,
and the mean of two reproducible readings was recorded in the variable ENXMEAN
(CDC, 2013d, 2013e). For the purpose of this analysis, eNO, a continuous variable, was
converted into a categorical variable and separated into quartiles.
Effect Modifier: Occupation
Occupation was as an effect-modifying variable. The type of occupation and
length of time spent in that particular occupation may cause eNO levels to increase or
decrease. NHANES 2007 to 2010 included a questionnaire about whether individuals
were currently working in or had worked in an occupation where there was a risk of NO
exposure. Any individuals who responded positively to any of the following questions
were considered at risk of exposure to NO and coded 1 = yes. Individuals who responded
negatively to all of these questions were considered not at risk and coded 0 = no (CDC,
2013f, 2013g). The questions were as follows:


In any job, have you ever been exposed to dust from rock, sand, concrete, coal,
asbestos, silica, or soil?



In any job, have you ever been exposed to dust from baking flours, grains, wood,
cotton, plants, or animals?
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In any job, have you ever been exposed to exhaust fumes from trucks, buses,
heavy machinery, or diesel engines?



In any job, have you ever been exposed to any other gases, vapors, or fumes?

Table 13 lists the inclusion questions along with more detail from NHANES 2007 to
2010.
Covariate Variables
Covariates included age, gender, race/ ethnicity, tobacco smoking, and body mass
index; whether someone smoked in the home; whether the subject ate or drank within the
last hour, ate nitrogen rich foods within the last 3 hours, ate nitrogen-rich vegetables
within last 3 hours, smoked within the last hour, exercised strenuously in the last hour,
used steroids within the last 2 days, had a cough, cold or other respiratory illness in last 7
days, or had ever been told they had asthma. A complete list of questions is found in
Tables 14 and 16 (CDC, 2013b, 2013c, 2013h, 2013i).
Variables – Questions and Coding
In this section, I describe the NHANES dataset questions and codes in detail. All
data came from National Health and Nutrition Examination Surveys 2007–2008 and
2009–2010.
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Demographic Variables:
Covariate data on age, gender, and race were part of “Demographic Variables and
Sample Weights” data files DEMO_E.xpt and DEMO_F.xpt (CDC, 2013h; 2013i). See
Table 8.
Table 8
Demographic Data – Description and Coding
Variable name

Description and coding

Variable type

Study code

RIAGENDER

Gender—male and
female

Covariate

Male, Female

RIDAGEYR

Age at screening
adjudicated—recode

Covariate

Age

RIDEETH1

Race/ ethnicity—
recode

Covariate

Mexican American,
Other Hispanic, NonHispanic White,
Non-Hispanic Black,
Other race/ Multiracial

The emphysema and chronic bronchitis data were part of “Medical Conditions”
documentation, data files MCQ_E.xpt and MCQ_F.xpt (CDC, 2013b; 2013c). See Table
9.
Table 9
COPD Determination: 2007-2010
Variable name

Description and coding

Study variable

MCQ160G

Ever told that you had
emphysema?
Ever told you had chronic
bronchitis?

COPD

MCQ160K

COPD
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The spirometry data were part of the “Spirometry—1st Test & 2nd Test
Bronchodilator Studies” documentation data files SPX_E.xpt and SPX_F.xpt (CDC,
2013j; 2013k). See Table 10.
This variable was measured using the GOLD standard that measures FEV1, and
FVC and was expressed as a ratio of FEV1/FVC (GOLD, 2010). This study used prebronchodilator spirometry testing. Measurements of FEV1 were divided by FVC for prebronchodilator spirometry testing. A ratio was calculated, and a stage of severity from I
to IV was given. Table 11 lists the variables used for the calculation.
Table 10
COPD Severity Determination: 2007-2010
Variable name

Description and coding

Study code

SPXNFVC

Baseline FVC (mL)

FVC—Spirometry

SPXNFEV1

Baseline FEV 1 (mL)

FEV— Spirometry
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Table 11
COPD Severity as Defined by GOLD
Severity

Characterized by airflow
limitation
FEV1/FVC < 0.70, FEV1
>= 80 % predicted

Criteria

Moderate (II)

FEV1/FVC < 0.70, 50 %
<= FEV1 <= 80 %
predicted

Symptoms usually progress
at this stage, with shortness
of breath typically developing
on exertion.

Severe (III)

FEV1/FVC < 0.70, 30 %
<= FEV1 <= 50 %
predicted

Shortness of breath typically
worsens at this stage and
often limits patient’s daily
activities. Exacerbations are
seen beginning at
this stage.

Very Severe (IV)

FEV1/FVC < 0.70, <30
% predicted or FEV1
<50 % predicted plus
chronic respiratory
failure

At this stage, quality of life
is very appreciably impaired,
and exacerbations may be
life-threatening.

Mild (I)

At this stage, the patient
may not be aware that their
lung function is abnormal.

Exhaled NO data was part of the “Exhaled Nitric Oxide” documentation data
files ENX_E.xpt and ENX_F.xpt (CDC, 2013d; 2013e). See Table12. The variable
ENXMEAN contained two reproducible eNO measurements from each participant. The
variable was divided into quartiles for this study. See Table 12.
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Table 12
Nitric Oxide Factors: 2007-2010
Variable name
ENXMEAN

Description and coding
2 reproducible FENO
measures (ppb)

Study code
Exhaled nitric oxide

Occupation data was part of the “Occupational—OCG Questionnaire”
documentation data files (CDC, 2013f; CDC, 2013g). See Table 13. Occupations with no
risk for NO exposure were coded as 0 and those at-risk were coded as 1. Those who
responded affirmative to any of the following questions listed in Table 13 were
considered at-risk and coded as 1.
Table 13
Occupation Data
Variable name
OCQ.510

Description and coding
Study code
In any job have you ever been exposed Exposure to rock,
to dust from rock, sand concrete, coal, sand, coal, etc.
asbestos, silica, or soil?

OCQ.530

In any job have you ever been exposed Exposure to baking
to dust from baking flours, grains,
dust, grains, cotton,
wood, cotton, plants, or animals?
plants, etc.

OCQ.550

In any job have you ever been exposed Exposure to exhaust
to exhaust fumes from trucks, buses,
fumes, trucks, buses,
heavy machinery, or diesel engines?
etc.

OCQ.570

In any job have you ever been exposed Exposure to other
to any other gases, vapors, or fumes?
gases/fumes

Covariate confounders that affect NO and COPD were part of the “Smoking –
Cigarette Use” documentation data files SMQ_E and SMQ_F, “Exhaled Nitric Oxide”

56
documentation data files ENX_E.rpt and ENX_F.rpt, and the “Medical Conditions”
documentation data files MCQ_E.rpt and MCQ_F.rpt (CDC, 2013b; 2013c; 2013d;
2013e; 2013l; 2013m). See Table 14.
Table 14
Covariate Confounding Questions for Nitric Oxide
Data set code

Question

Study code

ENQ040

Smoked last hour?

Smoked in last hour

ENQ050

Exercised strenuously
last hour?
Ate or drank last hour?

Exercised

ENQ060
ENQ070
ENQ080
ENQ090
ENQ100
MCQ010

Ate NO-rich vegetables,
3 hours?
Ate NO-rich meats, 3
hours?
Used oral or inhaled
steroids, 2 days?
Cough, cold, resp.
illness, 7 days?
Ever been told you had
asthma?

Ate or drank the last
hour
Ate NO-rich foods
Ate NO-rich foods
Used inhaled steroids
Respiratory illness
Asthma

Covariate data on smoking behavior was part of the “Smoking—Cigarette Use”
documentation data files SMQ_E.xpt and SMQ_F.xpt. (CDC, 2013l; 2013m). Smoking
status was divided into three categories, “nonsmoker,” “current smoker,” and “exsmoker.” A nonsmoker was defined as any individual who had smoked fewer than 100
cigarettes in their lifetime. Current smokers included all individuals who responded
positively to smoking at least 100 cigarettes in a lifetime and smoking cigarettes every
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day. Ex-smokers were defined as those who had smoked at least 100 cigarettes and who
replied that they no longer smoked cigarettes. See Table 15.
Table 15
Covariate—Smoking
Data set code

Question

Response

SMQ020

Smoked at least
100 cigarettes in
life?
Smoked at least
100 cigarettes in
life?
Do you now
smoke
cigarettes?
Do you now
smoke
cigarettes?

SMQ020

SMQ040

SMQ040

Study code

Yes

Individual
code
SMAQUEX2

No

SMAQUEX2

Never smokers

Every day

SMQ077

Current smokers

Some days

SMD641

Current smokers

Current smokers

Body mass index (BMI) data was part of the “Body Measures” documentation
data files BMX_E.xpt and BMX_F.xpt (CDC, 2013n; 2013o). See Table 16. Body mass
index was divided into three categories, “normal,” “medium,” and “obese.” Normal was
defined as any individual with a body mass index of less than 25. Overweight individuals
had a body mass index greater than or equal to 25 but less than 30. Obese individuals had
a body mass index greater than 30.
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Table 16
Covariate—Body Mass Index (BMI)
Data set code

Question

Response

BMXBMI

Body Mass
Index (kg/m**2)
Height (cm)

Yes

BMXHT

Individual
code
BMXBMI

Measurement BMXHT

Study code
BMI
Height

Data Analysis Plan
Data analysis was performed using STATA/ SE 12, a software program that is
able to manage large datasets such as those in the NHANES survey (STATA Corp).
Calculations included descriptive statistics, the chi-square test of association for
frequency comparison, proportional odds ration regression analysis, and subpopulation
regression analysis to test the association between eNO and COPD and the effect of
occupation.
Hypothesis 1: There is an association between eNO and self-reported physiciandiagnosed COPD (defined as presence of chronic bronchitis or emphysema) among adult
NHANES 2007 to 2010 participants. This hypothesis was tested using NHANES 2007 to
2010 self-reported data by combining the Emphysema and Chronic Bronchitis responses
to form the binary COPD variable. All positive responses to “Ever been told you had
chronic bronchitis?” or “Ever been told that you had emphysema?” were used to form the
binary COPD variable. The variable NO was created by separating the mean average of
individual response into quartiles. Descriptive statistics and chi-square analyses were
conducted first. Calculations included p-values for trend to check for dose–response
relationship, odds ratios, and corresponding 95% confidence intervals. Four models were
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created to test the hypothesis by logistic regression analysis. The first model used an
unadjusted univariable logistic regression analysis on all individual variables. The
second model was adjusted for sociodemographic variables (age, gender, race, and
smoking status) and tested with a multivariable regression analysis. The third model was
adjusted for factors that directly affect NO and tested using a multivariable logistic
regression analysis. These factors were: if someone smoked in the home; if the individual
ate or drank before the study, ate nitrogen rich meats, ate nitrogen-rich vegetables,
smoked in the last hour; if they exercised, used steroids, had a respiratory illness, or had
asthma. The fourth model was a multivariable regression analysis including all the
variables listed above.
Hypothesis 2: Increasing eNO levels are associated with increased COPD
severity, as defined by the GOLD standard. This hypothesis was tested using NHANES
self-reported data for 2007 to 2010 by aligning FEV1/ FVC ratios to the GOLD standard
stages for severity, associating observed ratios less than 70% lung capacity with predicted
values. Ratios greater than 70% lung capacity were considered normal and not contained
in the GOLD standard. The variable eNO (in quartiles) was based on responses to the
“FENO Measurement,” using the means of 2 reproducible measurements from each
individual. These means were then separated into quartiles. The hypothesis was tested by
analyzing the frequency of eNO by quartiles against the frequency of COPD severity as
defined by GOLD Stages I, II, III, and IV in pre-bronchodilator spirometry analysis. Data
for Stages III and IV data were few and combined into one variable, Stage III. Since the
outcome variable, COPD severity, is an ordinal variable, the proportional odds logistic
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regression analysis (also referred to as ordinal logistic regression analysis) was
performed. In the proportional odds model, the probability of a larger response is
compared to the probability of an equal or smaller response. A univariable ordered
logistic regressions analysis was performed first, followed by multivariable ordered
logistic regression analyses, adjusted for all confounding variables.
Hypothesis 3: The association between NO and COPD is modified by occupation.
This hypothesis was tested using NHANES 2007 to 2010 data by comparing occupation
with eNO and COPD results. At-risk occupations were coded as 1 and low-risk
occupations as 0. This variable was created with responses to the Occupation OCQ
questionnaire (CDC, 2013f; 2013g). The questions included: “In any job have you ever
been exposed to dust from rock, sand, concrete, coal, asbestos, silica, or soil?”; “In any
job have you ever been exposed to dust from baking flours, grains, wood, cotton, plants,
or animals?”; “In any job have you ever been exposed to exhaust fumes from trucks,
buses, heavy machinery, or diesel engines?”; and “In any job have you ever been exposed
to any other gases, vapors, or fumes?” To test this hypothesis, data were stratified by atrisk occupation. A univariable analysis and a subpopulation logistic regression analysis
were conducted. Odds ratios, along with the corresponding 95% confidence intervals,
were computed for eNO quartiles as described earlier.
Quality
NHANES quality control and quality assurance is in compliance with the 1988
Clinical Laboratory Improvement requirements (CDC, 2013a). Several methods were
used to monitor the quality of the analyses performed by the NHANES contract
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laboratories. First, the equipment and data collection in the MEC are calibrated and
checked before the analysis of the survey data is begun (CDC, 2013a). Second, the
quality testing performed in the MECs included analyzing “blind” split samples collected
during pretesting. Third, random repeat testing was completed on 5% of the samples.
Fourth, the laboratory personnel performance was monitored by NCHS and contract
consultants during unscheduled audits using a detailed quality assurance evaluation.
Observations of laboratory staff and feedback were provided on equipment use, specimen
collection and preparation, survey participant interaction, and survey protocol
implementation (CDC, 2013a). In addition, an annual retraining session was conducted.
Concerning data processing and preparation, NHANES has guidelines for NCHS and
contractors that contain standards for naming variables, filling missing values, and
handling missing records (CDC, 2013a). Comments were reviewed and recorded. Prior to
testing, all collection materials were screened by the CDC/ NCEH, Environmental Health
Laboratory Sciences.
Instrumentation and Materials
The data collection instrument for this study is secondary data from the NHANES
2007 to 2010 data set. NHANES contains information from interviews, physical
examinations, and laboratory results on a representative sample of noninstitutionalized
children and adults in the United States. Data sets of four consecutive years must be
weighted (CDC, 2013a). Data is available for public use. More information is contained
in the Data Weighing section.
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Ethical Considerations and Protection of Human Participants
NHANES data is free for public use. Participant information in NHANES is
protected by the Public Health Service Act (42 USC 242k) and Section 308(d) of that law
(42 USC 242m), the Privacy Act of 1974 (5 USC 552A), and the Confidential
Information Protection and Statistical Efficiency Act (PL 107-347). There are no ethical
concerns related to the recruitment of subjects, materials used, and data collection for this
dissertation. All participant data is anonymous and confidential and protected by the
CDC. Furthermore, the study was approved by the Walden University institutional
review board under reference number 12-12-13-0157824.
Summary
This quantitative study applied a hypothetico-deductive approach to analyzing the
association between NO and COPD using NHANES 2007 to 2010 data. Research areas
included analyzing NO and COPD (emphysema and chronic bronchitis), NO and COPD
severity, and the effect of occupation on the association between NO levels and COPD.
Chapter 4 presents the results of the analyses conducted to test the three hypotheses.
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Chapter 4: Results
The purpose of this quantitative study was to determine the association between
eNO and COPD. The research questions and accompanying hypotheses are listed below.


Research Question 1: Is there an association between eNO and COPD (chronic
bronchitis or emphysema) in adults?
o Hypothesis 1: There is an association between eNO and self-reported
physician diagnosed COPD (defined as presence of chronic bronchitis or
emphysema) among adult NHANES 2007 to 2010 participants.
o Hypothesis 2: Increasing eNO levels are associated with increased COPD
severity, defined by the GOLD standard.



Research Question 2: Does occupation modify the association between eNO and
COPD?
o Hypothesis 3: The association between NO and COPD is modified by
occupation.
I begin Chapter 4 with an overview of the descriptive characteristics and chi-

square analysis. The first hypothesis, testing the association between eNO and COPD,
was analyzed with four models. The first model was an unadjusted univariable logistic
regression analysis of all variables. Model 2 was adjusted for socioeconomic variables.
Model 3 was adjusted for factors that affect NO directly. Model 4 was adjusted for all
variables. Hypothesis 2 tested the association between eNO and COPD severity through
pre-bronchodilator spirometry analysis. The third hypothesis tested whether occupational
exposure is an effect modifier of the relationship between eNO and COPD with a
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subpopulation logistic regression analysis. Chapter 4 concludes with a summary and
transition into Chapter 5.
Descriptive Characteristics
NHANES is an annual study that combines interviews and physical
examinations of over 5,000 individuals in the United States (CDC, 2013a). The sample is
representative of the U.S. population (CDC, 2013a). There were 20,686 participants in
NHANES 2007 to 2010; however, the study sample was limited to participants 30 years
and older because COPD is rarely observed in younger age groups, resulting in a sample
size of 10,214 for the final analysis. Women made up 52% (n = 5,230) of the sample,
while 48% were male (n = 4,984). Non-Hispanic whites made up most of the sample at
71% (n = 4,982), followed by non-Hispanic blacks at 11% (n = 1,951). Nonsmokers
made up 53% (n = 5,287) of the study sample; 27% were ex-smokers (n = 2,815), and
20% were current smokers (n = 2,106). Thirty-five percent of responders were
overweight (n = 3,446) and 37% were obese (n = 4,274).
Exhaled NO data were provided by 81% (n = 7,474) of the sample. These results
were grouped into quartiles (see Table 17). Frequency distribution of factors that could
directly affect eNO levels ranged from as low as 0.6% of those reporting that they had
exercised strenuously in the last hour to as high as 52% for those who had eaten or drunk
within the last 3 hours before beginning the examination (Table 17).
Nearly 8% (n = 805) of study participants were told by a physician that they had
COPD (emphysema or chronic bronchitis). However, after conducting prebronchodilator spirometry analysis, 1,160 were confirmed to have COPD by pre-
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bronchodilator analysis. As a result, 11.4% of the entire study population were classified
as having Stage I (n = 608), 4.8% had Stage II (n = 478), and 0.7% had Stage III (n = 75)
COPD (Table 17). Forty-nine percent of study respondents (n = 4,927) worked in an atrisk occupation with the potential for exposure to NO.
Table 17
Descriptive Table
Variable
Age
30–39 yrs.
40–49 yrs.
50–59 yrs.
60–69 yrs.
70+ yrs.
Gender
Female
Male
Race
Non-Hispanic White
Other Hispanic
Mexican American
Non-Hispanic Black
Other Race/ Ethnicity
Smoking
Nonsmoker
Ex-Smoker
Current Smoker
BMI
Normal
Overweight
Obese
Factors that can directly affect NO levels
Ate or Drank within the Last Hour
Ate Nitrogen Rich Meats 3 Hours Before
Ate Nitrogen Rich Vegetables 3 Hours Before

n (unweighted)

weighted

2045
2057
1876
1960
2267

22.5
25.0
22.7
15.1
14.7

5230
4984

52.3
47.7

4892
1081
1723
1951
477

70.8
4.6
7.5
10.9
6.2

5287
2815
2106

53.1
27.0
19.8

2494
3446
4274

27.9
34.8
37.4

4525
257
311

51.9
3.0
4.0

table continues
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Variable
Exercised Strenuously Last Hour
Used Steroids in Last 2 Days
Cough, Cold, or Respiratory Illness Last 7 days
Ever Been Told you Have Asthma
Exhaled Nitric Oxide
1st Quartile (Mean = 6.2)
2nd Quartile (Mean = 11.8)
3rd Quartile (Mean = 17.6)
4th Quartile (Mean = 36.5)
COPD
No
Yes
Pre-Bronchodilator
Stage I
Stage II
Stage III & IV
At-Risk Occupation
Not at risk
At risk

n (unweighted)
61
369
1620
1294

weighted
0.6
4.1
15.5
12.9

2042
1797
1842
1793

22.1
20.5
20.0
18.8

9373
805
1160
608
477
75

92.5
7.2
11.4
6.9
4.8
0.7

4061
4927

42.7
49.4

Chi-Square Analysis
Chi-square analysis was conducted across all variables against the dependent
variable COPD (Table 18). Overall, age was significantly associated with COPD. The
prevalence of COPD increased by age. It was as low as 3.6% in the 30 to 39-year-old
category and as high as 12.5% in the 60 to 69-year-old category; it declined slightly to
10.5% in the 70+ year old category (p < 0.001). More women than men were diagnosed
with COPD (4.6 and 2.7 respectively, p < 0.001). Similarly, non-Hispanic whites had the
highest prevalence of COPD at 8.2%, followed by non-Hispanic blacks (6.2%), and other
Hispanics (5.6%, p < 0.001). Smoking was also significantly related to COPD. Exsmokers had the highest prevalence (12.4%), followed by current smokers (9.6%) and
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nonsmokers (4.1%, p < 0.001). The study respondents who were obese (BMI > = 30) had
a higher prevalence of COPD at 8.9% (p < 0.001) than either the normal and overweight
individuals.
The prevalence of COPD decreased as eNO concentrations increased by
quartiles (p < 0.001). All of the potential confounding factors that could affect eNO levels
were significantly associated with COPD. Finally, the study respondents who worked in
at-risk occupations had higher prevalence of COPD than those who did not work in atrisk occupations (8.7% vs. 5.3%, p < 0.001; Table 18).
Table 18
Chi-Square Analyses for the Association Between Various Independent Variables and
COPD
Variable
Age
30–39 yrs.
40–49 yrs.
50–59 yrs.
60–69 yrs.
70+ yrs.
Gender
Male
Female
Race
Non-Hispanic White
Other Hispanic
Mexican American
Non-Hispanic Black
Other Race/ Ethnicity
Smoking
Nonsmoker
Ex-smoker
Current Smoker

COPD

p- value

3.6
5.8
6.8
12.5
10.5

<0.001

5.6
8.7

<0.001

8.2
5.6
2.7
6.2
5.2

0.001

4.1
12.4
9.6

<0.001

table continues
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Variable
BMI
Normal
Overweight
Obese
Factors that could directly affect eNO
Ate or Drank within the Last Hour
Ate Nitrogen Rich Meats 3 Hours Before
Ate Nitrogen Rich Vegetables 3 Hours Before
Smoked Within the Last Hour
Someone Smokes in the Home
Exercised Strenuously Last Hour
Used Steroids in Last 2 Days
Cough, Cold, or Respiratory Illness Last 7 days
Ever Been Told you Have Asthma
Exhaled Nitric Oxide
1st Quartile
2nd Quartile
3rd Quartile
4th Quartile
At-Risk Occupation
Not at-risk
At risk

COPD

p- value

6.4
6.2
8.9

<0.001

6.5
6.4
7.6
12.2
14.2
4.0
30.9
10.2
25.2

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

8.7
6.1
5.6
4.8

<0.001

5.3
8.7

<0.001

Research Question 1: Hypothesis 1
Is there an association between eNO and COPD (chronic bronchitis or
emphysema) in adults?
Hypothesis 1: There is an association between eNO and self-reported physician
diagnosed COPD (defined as presence of chronic bronchitis or emphysema)
among adult NHANES 2007 to 2010 participants.
Four models were developed to analyze the hypothesis (Table 19). Model 1 was
unadjusted and used odds ratios and corresponding 95% confidence intervals between
eNO quartiles and COPD. Exhaled NO levels were grouped into quartiles: Quartile 1
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ranged from 3.5 ppb to 9.5 ppb (mean = 6.3), Quartile 2 from 9.5 ppb to 14.5 ppb (mean
= 11.8), Quartile 3 from 14.5 to 22.5 (mean = 17.6), and Quartile 4 ranged from 22.5 to
301 (mean = 36.5). The odds of COPD decreased as the amount of eNO increased from
as high as 0.68 (95% CI: 0.51–0.92) for Quartile 2 to as low as 0.53 (95% CI: 0.39–0.73)
for Quartile 4 (Table 19). When adjusted for age, gender, race, and smoking status, all
odds ratios became statistically nonsignificant (Model 2). The odds ratio of COPD for the
second and the third quartiles of eNO exposure remained statistically nonsignificant for
Models 3 and 4, and only reached statistical significance for the fourth quartile with a
43% and 40% decline in the odds of COPD for Models 3 and 4, respectively.
Table 19
Hypothesis 1 - Model Comparison
COPD
eNO

Model 1
OR (95% CI)

1st Quartile
2nd Quartile
3rd Quartile
4th Quartile

1.00
0.68
(0.51-0.92)
0.63
(0.44-0.89)
0.53
(0.39-0.73)

p-value

0.013
0.010
<0.001

Model 2
OR (95% CI)
1.00
0.90
(0.42-0.87)
0.85
(0.57-1.28)
0.79
(0.56-1.28)

p-value

0.554
0.431
0.155

Model 3
OR (95% CI)

p-value

1.00
0.94
(0.64-1.38)
0.91
(0.60-1.36)
0.59
(0.40-0.86)

0.76
0.63
<0.05

Model 4
OR (95% CI)
1.00
0.99
(0.66-1.49)
0.91
(0.58-1.44)
0.60
(0.42-0.87)

p-value

0.93
0.68
<0.05

Note. Model 1- unadjusted analysis of odds ratio and 95% confidence interval or OR(CIs)
Model 2 – Model adjusted for age, gender, race, and smoking odds ratio and 95% confidence interval or OR(CIs)
Model 3 – Model adjusted for factors that can directly affect nitrogen oxide levels (Ate or Drank within Last Hour, Ate Nitrogen Rich
Foods within the Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in
the Home, Exercised Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7
days, Ever Been Told you had Asthma) of odds ratio and 95% confidence interval or OR(CIs)
Model 4 – Model adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the
Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home,
Exercised Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7 days, Ever
Been Told you had Asthma of odds ratio and 95% confidence interval or OR(CIs)

Research Question 1: Hypothesis 2
Hypothesis 2: Increasing eNO levels are associated with increased COPD
severity, defined by the GOLD standard.
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The GOLD standard has four stages of severity. Data for stage III and IV
severity were limited and combined into one category, Stage III. Hence, COPD severity
was recategorized into Stage I (mild), Stage II (moderate), and Stage III (severe/very
severe; see Table 20). The prevalence of pre-bronchodilator COPD was 11.4%. Quartile
3 in Model 1 was significant (p = 0.004) but the odds ratio was far from the null (OR =
0.52), and quartile 4 was slightly better (OR = 0.77), demonstrating that confounders had
a profound negative association with COPD severity and eNO. All variables in Model 2
were insignificant, and the odds ratios varied significantly. Quartile 2 (OR = 1.29, 95%
CI: 0.80–2.10), quartile 3 (OR = 0.70, 95% CI: 0.41–1.20), and quartile 4 (OR = 1.02, 95
% CI: 0.68–1.54). Adjusting for confounders shifted the odds ratios in a positive
direction, demonstrating that adjusting for covariates shifted all three quartiles closer to
the null.
Table 20
Hypothesis 2 - Pre-Bronchodilator Spirometry Results
Model 1
p-value

Model 2

NO

OR (95% CI)

OR (95% CI)

p-value

1st Quartile

1.00

2nd Quartile

0.94 (0.64-1.38)

0.749

1.29 (0.80-2.10)

0.290

3rd Quartile

0.52 (0.34-0.80)

0.004

0.70 (0.41-1.20)

0.185

4th Quartile

0.77 (0.57-1.04)

0.082

1.02 (0.68-1.54)

0.907

1.00

Note. Model 1 – Unadjusted
Model 2 - Adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the Last 3
hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home, Exercised
Strenuously Last Hour, Used Steroids within the Last 2 days, Cough, Cold or Other Respiratory Illness in Last 7 days, Ever Been Told
you had Asthma
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Research Question 2: Hypothesis 3
Does occupational exposure modify the association between eNO levels and
COPD?
Hypothesis 3: The association between NO and COPD is modified by occupation.
In the unadjusted analysis (Model 1), among those who worked in at-risk
occupations, the odds ratio of COPD decreased from 0.78 (95% CI: = 0.56–1.12) in
Quartile 2 to 0.54 (95% CI: = 0.39–0.76) in Quartile 4 (see Table 21). The same trend
was not apparent for the not-at-risk group (Table 21). When adjusted for potential
confounders, the results did not change substantially (Model 2, Table 21).
Table 21
Hypothesis 3- Association Between Nitric Oxide and COPD Stratified by At-Risk
Occupation
At-Risk Occupation
Model 1
NO
1st Quartile
2nd Quartile
3rd Quartile
4th Quartile

Yes
OR (95% CI)
1.00
0.78 (0.56-1.12)
0.66 (0.40-1.08)
0.54 (0.39-0.76)

No
OR (95% CI)
1.00
0.49 (0.25-0.99)
0.58 (0.32-1.05)
0.52 (0.29-0.94)

Model 2
Yes
No
OR (95% CI)
OR (95% CI)
1.00
1.00
1.17 (0.77-1.77)
0.69 (0.29-1.64)
0.94 (0.55-1.59)
0.83 (0.38-1.81)
0.70 (0.51-0.97)
0.52 (0.26-1.03)

Note. Model 1 – unadjusted analysis.
Model 2 - Model adjusted for age, gender, race, smoking, BMI, Ate or Drank within Last Hour, Ate Nitrogen Rich Foods within the
Last 3 hours, Ate Nitrogen Rich Vegetables within Last 3 Hours, Smoked within the Last Hour, Someone Smokes in the Home,
Exercised Strenuously Last Hour, Used Steroids within the Last 2 Days, Cough, Cold or other Respiratory Illness in Last 7 Days, Ever
been told you had Asthma.

Summary
The first hypothesis tested the association between eNO and COPD. All four
models exhibited the same odds ratio trend in that the odds ratios decreased as the
concentration of eNO increased. The second hypothesis tested the association between
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eNO and COPD severity based on pre-bronchodilator measurements. Pre-bronchodilator
spirometry results showed no statistically significant relationship between eNO and
COPD. The third hypothesis evaluated the effect modification by occupation on the
association between NO and COPD. At-risk occupational exposure did not appear to
modify the association between eNO and COPD in this study. Chapter 5 interprets the
findings and compares the results to current literature.
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Chapter 5: Discussion, Conclusions, and Recommendations,
Overview
This study was performed to investigate the association between eNO and COPD
because airway inflammation is present in all forms of COPD and eNO is an established
biomarker for airway inflammation in asthmatics. Therefore, there may be a link between
eNO and COPD related airway inflammation. This study used NHANES 2007 to 2010
data for analysis. The analysis was restricted to individuals 30 years and over because
COPD is a progressive disease and manifests mainly in older individuals. This resulted in
a sample size of 10,214. The first hypothesis investigated the association between eNO
and self-reported physician-diagnosed COPD. The second hypothesis examined the
association between eNO and COPD severity as defined by the GOLD standard. The
GOLD standard classifies the degree of respiratory obstruction based on spirometry data
into four stages of severity. The greater the obstruction, the more severe the disease.
The first research question had two hypotheses, testing the association between
eNO and COPD. The first hypothesis tested the association between eNO and COPD
using four different models. Model 1 used a univariable logistic regression analysis.
Model 2 used a multiple logistic regression analysis adjusted for potential confounding
effects of sociodemographics variables such as race, age, gender, and smoking status.
Model 3 analyzed the association between eNO and COPD adjusted for factors that could
directly affect eNO levels such as eating nitrogen rich foods, exercising, and taking
medications. The fourth multiple logistic regression model adjusted for all variables listed
earlier.
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The second hypothesis tested the association between eNO and COPD severity, as
determined by pre-bronchodilator measurements, using proportional odds logistic
regression analysis (ordinal logistic regression). Because airway inflammation increases
as disease progression worsens, there may be a link between eNO levels and COPD
severity. COPD severity was calculated as the ratio of FEV1/FVC and was categorized
based on the GOLD standard into four stages: Stage I (mild), Stage II (moderate), Stage
III (severe), and Stage IV (very severe). There were limited Stage III and Stage IV data
available. Therefore, Stage III and IV were combined into a single category: severe/very
severe.
The second research question analyzed whether occupation modifies the
association between eNO and COPD. Working in certain occupations may put
individuals at risk of exposure to higher NO levels. Respondents who replied positively
to being exposed to harmful gases, dusts, or fumes were considered to be working in atrisk occupations (n = 4,927). Another 4,061 responded negatively to the same questions
and were considered as working in not-at-risk occupations.
Discussion
Research Question 1: Is There is an Association Between eNO and COPD in Adults?
The prevalence of COPD in this study was 7.2% (n = 805) based on physician
diagnoses. However, based on pre-bronchodilator spirometry analysis, 11.4% (n = 1,160)
of the study population was diagnosed with some form of COPD. The prevalence of
COPD severity was 6.9% for Stage I, 4.8% for Stage II, and 0.7% for Stage III. These
results are similar to the ones reported by Lindberg et al. (2006), who reported the
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prevalence of mild, moderate, and severe GOLD-COPD as 8.2%, 5.3%, and 0.7%,
respectively. The findings from my study further supports the argument made by earlier
researchers that COPD is often under- or misdiagnosed in the clinical setting (Bednarek
et al., 2008; Jochmann et al., 2010; Lehouck et al., 2010; Lindberg, Bjerg, Rönmark,
Larsson, & Lundbäck, 2006; Smidth et al., 2012; Spyratos et al., 2012). Routine use of
spirometry testing in outpatient settings should be encouraged to diagnose, treat, and
manage COPD cases early in the disease process to prevent the disease from progressing
to a later, more severe stage.
When examining the unadjusted analysis of eNO and COPD, all eNO quartile pvalues were statistically significant (Quartile 2 p = 0.013, Quartile 3 p = 0.010, and
Quartile 4 p < 0.001). Odds ratios decreased from 0.68 in Quartile 2 to 0.53 in Quartile 4.
However, when adjusted for factors directly affecting eNO (Model 3) and for all
variables (Model 4), only Quartile 4 remained statistically significant at p ≤ 0.05. These
results demonstrate that only higher concentrations of eNO are associated with lower
odds of COPD. The inverse relationship observed in the current study could possibly be
because only 4% of COPD patients were reportedly using steroids prior to the spirometry
testing during the NHANES examination and were likely to be clinically stable; eNO
levels rise during acute exacerbations, especially in patients hospitalized with severe
COPD (Agustí et al., 1999). Similar findings were also reported by Beg et. al. (2009) who
found a negative correlation between FEV1/FVC ratio and eNO concentration in COPD
patients (p = 0.028). In a small clinical study of 32 Dutch subjects (16 with COPD and 16
controls), Rutgers et al. (1999) reported no significant difference in eNO concentrations
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between subjects with and without COPD. Despite the small sample sizes, the results
from the current study were consistent with the three studies mentioned before.
Inflammation in COPD is mostly present in small airways and lung parenchyma.
This led researchers to partition total eNO into an airway and alveolar fraction. Brindicci
et al. (2005) found that COPD severity correlated with an increase in the alveolar fraction
of exhaled NO, CalvNO, However, their results were not confirmed by Lehouck et al.
(2010) and Bazeghi et al. (2011) who found no correlation between eNO, CalvNO, and
COPD severity, consistent with the results of the current study. Hence, the findings of
this current study confirm previous data and weaken the prospect of using eNO as a
biomarker for COPD.
Research Question 2: Does Occupation Modify the Association between eNO and
COPD?
To my knowledge, this is the first study that has explored effect modification by
occupational exposures. This study did not find at-risk occupations to modify the
association between eNO and COPD. Although the adjusted odds ratio declined as eNO
levels increased, none of the results were statistically significant. This study defined atrisk group as anyone who was ever exposed to a wide range of factors such as dust from
rock, sand, asbestos, baking flours, and grains. (see Table 12). This study did not take
into account the time between exposure and testing, duration of exposure, and amount of
particulates, dust, or fumes the participant was exposed to, all of which could potentially
confound the relationship between eNO and COPD. Whether the inverse relationship,
albeit statistically nonsignificant, observed in the current study is due to the presence of
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relatively stable COPD patients or an artifact of data should be explored in future studies.
Exhaled NO is a known biomarker of airway inflammation in occupational asthma
patients (Demange et al., 2009; Lund et al., 2000; Tossa et al., 2009; Tossa et al., 2010)
and occupational exposures have been shown to modify the association between eNO
and asthma (Tossa et al., 2010). However, the results of the current study conclude that
occupation does not modify the relationship between eNO and COPD. More studies are
needed to confirm these findings.
Implications for Social Change
There were two defining questions for COPD in this study; “ever been told you
had emphysema?” and “ever been told you had chronic bronchitis?” Eight-hundred five
participants replied positively to either question and were labeled as having COPD.
COPD is often misdiagnosed or underdiagnosed in the clinical setting, primarily due to
underutilization of spirometry in outpatient settings. This study confirms previous data
suggesting that spirometry is more sensitive than self-report for detecting early forms of
COPD. Effective use of spirometry testing in outpatient settings can lead to early
diagnosis and treatment. This will likely reduce progression to later stage COPD, fewer
comorbidities and complications related to COPD, a decline in mortality, a decrease in
healthcare expenditure, and will result in a healthier population.
Limitations
NHANES is subject to both sampling and nonsampling errors. Interview data are
based on self-reports and subject to error because of recall bias and the participant not
understanding the question. Physical examination and laboratory data are subject to
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variations in the measurements. In addition, there is the possibility of examiner or
physician error. In order to prevent error, detailed protocols were created and audited by
public health professionals and the scientific community. Problems and
misinterpretations can be prevented by reviewing the documents, reading the data
collection protocols and data collection instruments, and conducting descriptive
evaluation of the data at the onset (CDC, 2013a). Prior to data collection, the NHANES
staff takes comprehensive training and annual refresher training courses. Selection bias
was minimized, as NHANES uses a complex, multistage probability sampling technique
for selection. In addition, participants who were interviewed or examined were selected
by random subsamples or statistically defined (CDC, 2013a).
Because the Stata statistical software package uses listwise (casewise) deletion in
regression analysis (i.e., if a value for one variable is missing, an entire record is
excluded from the analysis), it has the potential to drastically reduce the sample size and
power of a study. To overcome this limitation, an indicator category for missing values
was created for confounding variables with 10% or more missing values. In this case, the
confounding variables were: ate or drank in the last hour, ate NO rich meats, ate NO rich
vegetables, performed strenuous exercise in the last hour, and used steroids. Although
the current study included a large number of potential confounding variables, residual
confounding due to unmeasured variables could not be ruled out.
Data for GOLD Stage III and IV severity were few. To overcome this limitation,
Stage III and IV data were combined into a single category (Stage III: severe/ very
severe). As a result, the Stage III-IV sample size for this study was larger than that of
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most previous studies. Asthma and COPD can coexist, and sometimes it is difficult to
separate them clinically (de Marco et al., 2013; Kim & Rhee, 2010). There were 366
subjects in the current study who had both asthma and COPD. Removing asthmatics from
the analyses did not change the results. Therefore, to maintain the appropriate power, I
chose to leave the asthma variable in multiple logistic regression analyses as a potential
confounder. Lastly, due to the cross-sectional nature of the data, reverse causation cannot
be ruled out.
Dissemination of Findings
The goal is to present and publish preliminary and final results at conferences
attended by clinicians and researchers interested in COPD. Applications for
presentations, poster sessions, and abstracts at several conferences will be completed and
submitted. The two proposed conferences are the Breath Analysis Summit and the
European Respiratory Society annual conferences to be held in 2015.
Conclusion
This study finds no association between eNO and COPD and COPD severity.
There may be a correlation between high levels of eNO and COPD, but further studies
are needed. In addition, GOLD Stage III and IV data were limited, and a larger sample
size of later-stage COPD severity is needed to effectively investigate the association.
Furthermore, at-risk occupation was not found to be an effect modifier. Future studies
that include exposure times and duration are needed to further test this association. An
important finding of this study is that COPD is under- or misdiagnosed in the clinical
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setting. Therefore, routine use of spirometry should be encouraged for diagnosis and
management of COPD in outpatient settings.
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Appendix A: Effect of Covariates
The type of covariate affects the association between eNO and COPD. Regression
analyses showed smoking status to be significant; and, as stated above, ex-smokers had a
higher odds ratio, so inclusion of only one type of smoker can skew results. Studies
adjusting only for age, race and gender, may find no association between eNO and
COPD, as in this study sociodemographics was insignificant. Studies that include other
covariates such as eating nitrogen rich foods 3 hours before the study, smoking
behaviors, having another respiratory illness, and exercising before the study may or may
not find an association between eNO and COPD depending on which factors are included
in the study and the levels of eNO. In this group, only smoking in the home, exercising
before the exam, taking steroids, having a respiratory illness, and having asthma were
significant. In addition, low levels of eNO are not associated with COPD, whereas high
levels of eNO are associated with COPD in all models except when adjusting for
sociodemographic data only. Based on this study, neither a nitrogen-rich diet nor exercise
was significant across all models (p > 0.05).
Overall, the study found that the prevalence of COPD increases with age, except
in the 70+ age category, where the odds ratios actually declined. There was a significant
correlation between COPD and steroids across all models (p < 0.05). This confirms the
work by Liu et al. (2007), which determined there was an association between eNO,
COPD, and individuals taking glucocorticoids (p < 0.00005) (Liu et al., 2007).
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Appendix B: New NHANES Sampling Methodology
A new sampling methodology was introduced in 2007 to 200. In the past, all
Hispanics had been oversampled compared to Mexican Americans. The 12 to 15 and 16
to 19-year age groups were combined to form a single 12 to 19-year-old group for all
races; and for minority groups, the 40 to 59-year groups were split into 40 to 49 and 50 to
59. The last change was that pregnant women were no longer oversampled.
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Appendix C: Reference Equations
Reference equations are derived from Hankison, J. L., Odencrantz, J. R. & Fedan, K. B.
(1999). Spirometric references values are derived from a sample of the general U.S.
population. American Journal of Respiratory Critical Care Medicine. 159(1), 179-187.
doi: 10.1164/ajrccm.159.1.9712108
FVC Reference Equations
Male
 Non-Hispanic White= -0.1933+0.00064*ager0.000269*ager*ager+0.00018642*ht*ht
 Non-Hispanic Black (African American) = -0.15170.01821*ager+0.00016643*ht*ht
 Mexican American = 0.2376-0.00891*ager0.000182*ager*ager+0.00017823*ht*ht
 Other Race= Non-Hispanic White *0.88
Female
 Non-Hispanic White =-0.3560+0.01870*ager0.000382*ager*ager+0.00014815*ht*ht
 Non-Hispanic Black= -0.3039+0.00536*ager0.000265*ager*ager+0.00013606*ht*ht
 Mexican American= 0.1210+0.00307*ager0.000237*ager*ager+0.00014246*ht*ht
 Other Race = Non-Hispanic White *0.88
FEV1 Reference Equation
Male
 Non-Hispanic White =0.5536-0.01303*ager0.000172*ager*ager+0.00014098*ht*ht
 Non-Hispanic Black =0.3411-0.02309*ager+0.00013194*ht*ht
 Mexican American =0.6306-0.02928*ager+0.00015104*ht*ht
 Other Race = Non-Hispanic White *0.88
Female
 Non-Hispanic White=0.4333-0.00361*ager0.000194*ager*ager+0.00011496*ht*ht
 Non-Hispanic Black= 0.3433 - 0.01283*ager0.000097*ager*ager+0.00010846*ht*ht
 Mexican American= 0.4529-0.01178*ager-0.000113*ager*ager+0.00012154*ht*ht
 Other Race= Non-Hispanic White *0.88
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